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ABSTRACT 
During the past decade, the modulation of adult neurogenesis has been an intensively studied area of neuroscience 
due to the implications for understanding of physiological mechanisms in the adult brain and the potential clinical 
applications for neuropsychiatric disorders. This research has resulted in countless discoveries during a relatively 
short period of time elucidating mechanistic details about where adult neurogenesis takes place, how the process of 
neurogenesis occurs and how this process can be regulated at several different steps by, not only endogenous 
mechanisms which normally maintain a homeostasis of adult neurogenesis, but also by exogenous regulation using 
genetic and pharmacological modulations to manipulate steps of the process. The modulation of adult neurogenesis 
has been demonstrated to notably occur as a result of chronic antidepressant treatment which affects several stages of 
this process resulting in increased adult neurogenesis. A consensus of studies examining the importance of this 
modulation agree that this increase could be an integral and important part of the behavioral effects of antidepressant, 
indicating that increased neurogenesis is a part of the therapeutic process in the majority of treatment methods. 
Questions remain though regarding how neurogenesis is involved in modulating mood as a consensus on this matter 
finds that decreases in adult neurogenesis per se do not induce depression. However, recent studies indicate that adult 
neurogenesis is important in the regulation of stress, suggesting that a consequence of decreases in adult neurogenesis 
may play a role in the dysregulation of this endocrine system in combination with severe or chronic stress which may 
eventually result in depression. These findings highlight the potential significance of treatments which have the 
potential to increase adult neurogenesis during pathological states to reach stable levels.  
Current findings indicate that one of the most important and accessible systems in modulating neurogenesis is the 
serotonergic system, as exemplified by the potent ability of serotonin enhancing drugs such as the antidepressant 
fluoxetine to increase neurogenesis. A first set of studies present in this thesis investigate the neurogenic potential in 
the hippocampus of proteins of the S100 family associated with the serotonergic system including p11 and S100B. 
The first of these studies uses a genetic deletion of p11 in mice. Results from these experiments demonstrate that 
mice lack a neurogenic and behavioral response to fluoxetine, seen in normal mice. This finding indicates that p11 is 
involved in the antidepressant mechanism of fluoxetine. Further examination into potential mechanisms revealed that 
p11 is highly expressed in interneurons which also express low levels of 5-HT1B and 5-HT4 receptors, of which p11 
is a known adaptor protein. Interneurons are known to regulate aspects of adult neurogenesis indicating a possible 
mechanism through which p11 may modulate the neurogenic and furthermore behavioral effects of this 
antidepressant. A subsequent study identifies other areas of the brain potentially involved in depression which express 
p11 and 5-HT1B and 5-HT4 receptors. The last of these S100 studies uses a genetic amplification of S100B in mice 
to investigate its potential role in adult neurogenesis and revealed that S100B mice have an increased baseline level of 
cell proliferation which however did not translate into an increase in total neurogenesis. Furthermore, these mice 
display a normal neurogenic and behavioral response to fluoxetine. These results indicate that S100B is involved in 
cell proliferation though not other aspects of neurogenesis. Furthermore, S100B may be partially involved in aspects 
of neurogenesis enhancing drugs and highlight the potential benefits of modulation of this protein.  
Besides the serotonergic system, other neurotransmitter systems have been implicated in the regulation of adult 
neurogenesis, including the dopaminergic system. Altered dopamine levels are associated with several disorders of 
the brain with neuropsychiatric complications. Furthermore this system, in similarity to the serotonergic system, is a 
primary target of pharmacological therapies for neuropsychiatric disorders. A second set of studies therefore further 
investigated effects of pharmacological and genetic modulation of the dopaminergic system on adult neurogenesis. 
The first of these studies investigated the neurogenic and behavioral effects of the drug sarizotan which targets both 
the serotonergic and dopaminergic system. This drug has previously been shown to have potential antidyskinetic 
beneficial effects against involuntary movements seen in Parkinson’s disease and therefore we investigated effects of 
this drug in an animal model of Parkinson’s disease in which dopaminergic afferents are lesioned unilaterally. In the 
lesioned hemisphere, sarizotan increased cell proliferation in two neurogenic regions of the lateral ventricles and the 
hippocampus. Sarizotan in combination with the anti-Parkinsonian drug L-DOPA, also increased ongoing 
neurogenesis in the hippocampus. Furthermore, sarizotan had antidepressant-like activity in the forced swim test in 
lesioned animals. These findings indicate that targeting of both the serotonergic and dopaminergic systems may be an 
effective modulator of aspects of neurogenesis and behavior in certain pathologies. For example sarizotan may, in 
addition to antidyskinetic effects, have antidepressant potential in the frequently seen subgroup of Parkinson’s disease 
patients who also suffer from depression. 
 The numerous studies regarding purely dopaminergic regulation of adult neurogenesis in either the lateral 
ventricles or hippocampus have resulted in conflicting data suggesting a complex regulation in which several 
receptors may be involved. Currently available data suggest expression of the D3 receptors in the proliferative zone 
of the hippocampus indicating a role in adult neurogenesis. The role of the D3 receptor using a genetic deletion of this 
receptor in mice was therefore investigated. A robust increase was found in baseline levels of cell proliferation and 
ongoing neurogenesis in these mice, though not in cell survival. Furthermore, pharmacological modulation using the 
preferential D3 antagonist S33138 had a similar effect on cell proliferation, although less robust. Thus, in the 
hippocampus, the D3 receptor appears to act inhibitory on cell proliferation. Previous indicating that D3 is expressed 
in proliferating cells indicates that this may be a direct effect of dopamine whereas expression of D3 and D2 receptors 
on niche astrocytes may in contrast indirectly stimulate cell proliferation. This study further highlights how 
modulation of the dopaminergic system affects adult neurogenesis and may ultimately have significance for 
pathologies in which adult neurogenesis is affected.  
In summary, these findings exemplify the numerous different ways in which adult neurogenesis can be modulated 
which is also indicative of the situations in which adult neurogenesis can be defective, potentially contributing to 
disease. Studies presented in this thesis have via the use of genetic manipulation as well as pharmacological 
compounds highlighted specific proteins and pharmacological targets which can be used to modulate aspects of 
neurogenesis, having potential clinical significance for neuropsychiatric disorders in which adult neurogenesis is 
affected.  
  
 
 
 
  
 
 
  
LIST OF PUBLICATIONS 
 
 
I.  Martin Egeland, Jennifer Warner-Schmidt, Paul Greengard & Per Svenningsson. (2010) 
Neurogenic effects of fluoxetine are attenuated in p11 (S100A10) knockout mice. 67(11),  
1048-56. 
Biological Psychiatry 
 
II.  Martin Egeland, Jennifer Warner-Schmidt, Paul Greengard & Per Svenningsson. (2011) 
 Co-expression of serotonin 5-HT (1B) and 5-HT (4) receptors in p11 containing cells in 
cerebral cortex, hippocampus, caudate-putamen and cerebellum. 61(3), 442-50. 
Neuropharmacology 
 
III.  Martin Egeland, Vasco Sousa & Per Svenningsson. (2012) 
Changes in basal and fluoxetine-induced adult neurogenesis and depression-related 
behaviors in transgenic S100B over-expressing mice. 
Manuscript 
 
IV.  Xiaoqun Zhang*, Martin Egeland* & Per Svenningsson. (2011) 
Antidepressant-like properties of sarizotan in experimental Parkinsonism. 218(4),621-34. 
Psychopharmacology 
 
*shared first-authorship 
 
V.  Martin Egeland,  Xiaoqun Zhang, Mark J. Millan & Per Svenningsson. (2012) 
D3 receptor blockade via genetic deletion or the novel atypical antipsychotic S33138 
increases adult hippocampal neurogenesis and Delta FosB expression. 
Manuscript 
 
 Additional publication during PhD study 
 
i.  Mark J. Millan, Per Svenningsson, Charles R. Ashby, Jr., Michael Hill, Martin Egeland, 
Anne Dekeyne, Mauricette Brocco, Benjamin Di Cara, Francoise Lejeune, Nitza 
Thomasson, Carmen Munoz, Elisabeth Mocaer, Alan Crossman, Laetitia Cistarelli, 
Sylvie Girardon, Loretta Iob, Sylvie Veiga, and Alain Gobert  (2008).  
S33138, A Preferential Dopamine D 3 versus D 2 Receptor Antagonist and Potential 
Antipsychotic Agent. II. A Neurochemical, Electrophysiological and Behavioral 
Characterization in Vivo. 324(2), 600-611. 
Journal of Pharmacology and Experimental Therapeutics 
 
  
CONTENTS 
Introduction __________________________________________________________ 1 
Background Information about Adult Neurogenesis ____________________________ 1 
Historical Perspective ____________________________________________________________ 1 
The Process of Adult Neurogenesis _________________________________________________ 1 
Endogenous Regulation ___________________________________________________________ 2 
Functional Importance ____________________________________________________________ 4 
Relevance to Disease _____________________________________________________________ 5 
Potential Modulators of Adult Neurogenesis Relevant to Studies __________________ 9 
Serotonergic modulation __________________________________________________________ 9 
Potential modulation of adult neurogenesis via p11 __________________________________ 9 
Potential modulation of adult neurogenesis via S100B _______________________________ 11 
Dopaminergic modulation ________________________________________________________ 12 
Potential modulation of adult neurogenesis via modulation of dopamine signaling _________ 12 
Aims _______________________________________________________________ 17 
Methodological Considerations _________________________________________ 18 
Cell proliferation _______________________________________________________________ 18 
Ongoing Neurogenesis __________________________________________________________ 19 
Cell Survival __________________________________________________________________ 20 
Results and Discussion ________________________________________________ 21 
Genetic and Pharmacological Modulation of Adult Neurogenesis ________________ 21 
Genetic Modulation of S100 Proteins and Serotonergic Signaling _________________________ 21 
Genetic ablation of p11 attenuates the neurogenic response to fluoxetine (Papers I & II) ____ 21 
Genetic amplification of S100B expression increases cell proliferation (Paper III) _________ 23 
Pharmacological Modulation of Dopaminergic and Serotonergic Signaling _________________ 26 
Sarizotan increases cell proliferation in neurogenic niches (Paper IV) ___________________ 26 
Genetic and Pharmacological Modulation of D3 Receptor Signaling _______________________ 30 
Genetic ablation and pharmacological blockade of the D3 receptor increases hippocampal cell 
proliferation (Paper V) ________________________________________________________ 30 
Functional and Translational Relevance for Neuropsychiatric Disorders __________ 36 
Relevance of modulation of p11 for depression (Papers I & II) _________________________ 36 
Relevance of S100B for depression (Paper III) _____________________________________ 37 
Relevance of treatment with Sarizotan (Paper IV) ___________________________________ 38 
Relevance of D3 receptor modulation (Paper V) ____________________________________ 39 
Concluding remarks __________________________________________________ 40 
Conclusions _________________________________________________________ 41 
Acknowledgements ___________________________________________________ 42 
References __________________________________________________________ 42 
 
  
LIST OF ABBREVIATIONS 
5,7 DHT 5,7-dihydroxytryptamine 
 
L-DOPA 
L-3,4-
dihydroxyphenylalanine 
6-OHDA  6-hydroxydopamine  MAM methylazoxymethanol 
AIMS 
abnormal involuntary mov
ements 
 
MDMA 
3,4-
Methylenedioxymethamphe
tamine 
AN adult neurogenesis 
 
MPTP 
1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine 
ANOVA analysis of variance  NGF nerve growth factor 
ANP  
amplifying neural progenit
ors 
 
NIH 
Novelty induced 
hypophagia 
BAC 
bacterial artificial 
chromosome 
 
NMDA  N-methyl-D-aspartate 
BDNF 
brain-derived neurotrophic 
factor 
 
NSF novelty suppressed feeding 
BrdU 5-bromo-2'-deoxyuridine 
 
PCNA 
proliferating cell nuclear 
antigen 
CCK cholecystokinin  PD Parkinson’s disease 
CNS central nervous system  PHH3 phospho-Histone H3 
CNTF ciliary neurotrophic factor 
 PSA-
NCAM 
poly-Sialated Neural Cell 
Adhesion Molecule 
D3R dopamine D3 receptor 
 
QNP 
quiesentSHH neural progeni
tors 
DCX doublecortin  qPCR real-time PCR 
DNA deoxyribonucleic acid  RMS  rostral migratory stream 
ECT electroconvulsive therapy  SFN society for Neuroscience 
EGF epidermal growth factor  SGZ Subgranular zone 
FACS 
fluorescence Activated Cell 
Sorting 
 
SHH sonic hedgehog homolog 
FGF-2 fibroblast growth factor 
 
SSRI 
selective serotonin reuptake 
inhibitor 
FST forced swim test  SVZ subventricular zone 
GABA γ-Aminobutyric acid  TCA tricyclic antidepressants 
GFP green fluorescent protein  TG transgenic 
HPA 
hypothalamic-pituitary-
adrenal 
 
TST Tail suspension test 
IL-6 interleukin-6 
 
VEGF 
vascular endothelial growth 
factor 
KO Knock-out  WT  Wild -type 
 
Introduction 
  1 
INTRODUCTION   
 
BACKGROUND INFORMATION ABOUT ADULT NEUROGENESIS 
Historical Perspective 
Adult neurogenesis (AN) is one of the fastest growing areas in neuroscience so far in 
the 21st century. This topic has gone from being an idea that was relatively disregarded 
before the end of the last century to having presently thousands of publications. This 
topic has also been riveted with controversy since its introduction, controversy which 
has to date shown no signs of dissipating. Even the suggested existence of adult 
neurogenesis was controversial due to the long standing dogma that neurogenesis does 
not occur after development. Studies published by Altman and colleges in 1960s began 
to change this dogma which however did not fall easily due to technical limitations 
which left room for doubt in these studies (Altman & Das 1965). Several decades later, 
the technical breakthrough of BrdU labeling allowed the positive identification of AN 
in first birds followed by mammals (Goldman & Nottebohm 1983; Gould et al. 1992). 
These findings were later confirmed in primates as well as finally in humans, putting a 
definitive end to the century old dogma that neurogenesis does not occur in adulthood 
(Eriksson et al. 1998; Gould et al. 1999).  
 
The Process of Adult Neurogenesis 
It is now generally accepted by the scientific community that neurogenesis continues in 
adults in two regions, the subventricular zone (SVZ) of the lateral ventricles and the 
subgranular zone (SGZ) of the dentate gyrus in the hippocampus, which together make 
the neurogenic niches (Fig. 1). Adult born neurons have also been found in other areas 
of the brain, albeit only under pathological circumstances, including the striatum, 
neocortex, amygdala and hypothalamus (see Balu & Lucki 2009 for review). Adult 
neurogenesis is a complex process which is remarkably similar in both of the 
neurogenic niches although there are differences. The process begins within the 
neurogenic niches with the stem cells, the identity and lineage of which has been an 
area of much research (see Ming & Song 2011 for review). These cells are currently 
thought to be radial glia-like cells in both niches.  
In the SGZ of the hippocampal dentate gyrus, these cells, due to their low proliferative 
rate, are also known as quiescent neural progenitors (also Type I cells) and divide either 
symmetrically, giving rise to identical progeny, or asymmetrically giving rise to cells 
which eventually differentiate into cells known as amplifying neural progenitors (also 
known as type IIa cells) (Encinas et al. 2006). These amplifying neural progenitors 
divide actively thus increasing rapidly the proliferative pool from which adult neurons 
will be derived. At this point, new cells reach a critical point (1-4 days) at which they 
become apoptotic or continue to differentiate (Sierra et al. 2010). Those cells which are 
neuronal-lineage fate-determined are called neuroblasts (also known as D2 and 3 cells 
or Type IIb and III cells). These neuroblasts or immature neurons continue to mature 
and over a period of several weeks. Immature neurons go through several 
developmental changes during this time and display interesting properties different 
from mature cells including a transient low membrane capacitance (Ge 2006).  
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Eventually these cells migrate into the granular layer and integrate into the pre-existing 
circuitry of the dentate gyrus ( van Praag et al. 2002).  
In the SVZ of the lateral ventricles, the process is similar with the radial glia-like cells 
(also known as B cells) giving rise to the transient amplifying progenitor cells (C cells). 
These in turn give rise to the neuroblasts (A cells) which migrate through the rostral 
migratory stream (RMS) to the olfactory bulb where they differentiate into functional 
interneurons (Lois & Alvarez-Buylla 1993). 
 
Endogenous Regulation  
Endogenous regulation of AN can occur at various stages in the process. The 
complexity of AN and the possibility for modulation at numerous of these steps has 
meant that the list of known factors which regulate AN has increased immensely since 
the re-discovery of AN during the past decade. These factors can affect a single or 
several aspects of AN in a bi-directional manner, thus acting either inhibitory or 
stimulatory on aspects of AN. For detailed reviews of specific details of these factors 
see Ming & Song 2011 and Balu & Lucki 2009. Although these many of these factors 
affect both neurogenic niches, the majority of studies have been performed in the SGZ 
and therefore the following references refer to this niche unless otherwise stated.  
Among the many endogenous factors which affect neurogenesis are those which 
regulated the early stages of the process, the morphogens. These factors regulate 
maintenance, activation, and fate choice of adult neural precursors and include well 
known and characterized members such as Notch, Shh, Wnt and Ephrins (see Balu & 
Lucki 2009). 
 Some of the most studied regulators of AN are growth factors and neurotrophins 
(reviewed by Zhao et al. 2008 and Balu & Lucki 2009). A variety of growth factors are 
potent modulators of cell proliferation and some cell survival, inducing increased total 
neurogenesis. These include Fibroblast-growth factor-2 (FGF-2), Insulin-like growth 
factor-I (IGF-I), and Vascular endothelial growth factor (VEGF) (see Balu & Lucki 
2009).  Similar to the growth factors, several neurotrophic factors are also known be 
Figure 1 A schematic 
representation of the neurogenic 
niches in the rodent brain. 
(A) A sagittal section view of 
an adult rodent brain 
highlighting the two restricted 
regions that exhibit active adult 
neurogenesis: dentate gyrus 
(DG) in the hippocampal 
formation (HP), and the lateral 
ventricle (LV) to the rostral 
migratory stream (RMS) to the 
olfactory bulb (OB). 
(B) A schematic illustration of 
the neural stem cell niche in the 
subventricular zone (SVZ).  
(C) A schematic illustration of 
the neural stem cell niche in the 
subgranular zone (SGZ) in the 
dentate gyrus. 
Modified from (G.-L. Ming & 
Song 2011) 
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potent regulators of aspects of AN including neurotrophins, such as brain derived 
neurotrophic factor (BDNF) and nerve growth factor (NGF), as well as neurotrophic 
cytokines, such as ciliary neurotrophic factor and interleukin-6 (IL-6) (Zhao et al. 
2008). BDNF is one of the extrinsic factors most associated with depression and 
therefore much focus has been placed on this neurotrophic factor, specifically with its 
regulation of aspects of AN. Studies of this factor have revealed that BDNF is involved 
in the effects of many other factors which promote AN, for example increasing the cell 
survival of new neurons during antidepressant treatment (Sairanen et al. 2005). 
However the effects of BDNF on cell proliferation remain unclear with results from 
transgenic animal models giving mixed results (see Balu & Lucki 2009). NGF is 
similarly thought to increase cell survival (Frielingsdorf et al. 2007). 
Another major endogenous group of factors regulating AN are neurotransmitters. 
This group has been widely studied due to the ease of using specific pharmacological 
tools and also due to the fact that many prescribed clinical drug treatments and potential 
drugs target neurotransmitter receptors. Neurotransmitters which have been indicated to 
regulate AN include glutamate, noradrenaline, acetylcholine, γ-amino-butyric acid 
(GABA), dopamine and serotonin. Early on in the study of neurogenesis, it was 
demonstrated that afferents releasing glutamate in the dentate gyrus have an inhibitory 
effect on cell proliferation (E Gould et al. 1992). However later studies indicated that 
the regulation of glutamate is complex and has differential effects via different 
receptors (see Ming & Song 2011). The role of noradrenaline is less well understood 
and less studied although it appears that it regulates both cell proliferation and cell 
survival (Rizk et al. 2006; Kulkarni et al. 2002). The role of acetylcholine on the other 
hand has been widely studied and data from numerous studies indicates a likely role in 
proliferation, differentiation and integration with further data also indicating a role in 
survival (for review see Bruel-Jungerman et al. 2011). GABA acts normally as an 
inhibitory neurotransmitter and is released by interneurons of which, in the adult 
hippocampus, there are various types (Parra et al. 1998). In both the SGZ and SVZ,  
GABA appears to interact specifically in the neurogenic process and actually stimulates 
immature neurons rather than inhibiting via GABA-A receptors expressed during the 
first 2-3 weeks of neural progression (Tozuka et al. 2005). This stimulation has 
furthermore been demonstrated to promote progenitor differentiation and also has a role 
in synaptic integration ultimately affecting survival (Ge 2006; Tozuka et al. 2005). It 
has also been suggested that GABA may play a role in the migration of adult born 
neural progenitors (Ge et al. 2007). Results from specific studies modulating GABA 
receptors indicate that GABA does not affect cell proliferation (Earnheart et al. 2007). 
Due to the pertinent relevance to neuropsychiatric disorders, serotonergic and 
dopaminergic modulation has been studied widely and is also of particular focus to this 
thesis and therefore elaborated upon in following sections.  
The preceding section briefly introduces a much larger area of study. Indeed there are 
numerous other endogenous regulators including intracellular factors and not to 
mention epigenetic regulation which play important roles in the regulation of AN. A 
whole other area is the study of exogenous regulators such as environmental regulation 
including physical exercise, enriched environment and learning, all which have 
beneficial effects on AN. In addition, exogenous factors can also have a negative effect 
on AN, for example stress which is further explored in later sections.  Exogenous 
compounds and treatments which potentially regulate AN have also been an area of 
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great interest, particularly with regards to clinical applications. These are explored 
further in the section regarding AN and disease. 
 
Functional Importance  
The function of AN has been a critical question since the re-discovery of AN in the 
1990’s with many labs using various techniques to ablate AN and assess the 
consequences on behavior. This investigation has however not been without hurdles. 
Investigators have used several different methods with which to ablate AN including 
chemical anti-mitotic agents such as methylazoxymethanol (MAM), global and focused 
radiation and more recently the development of various genetic and molecular 
biologically driven ablation of neurogenic populations at specific time points allowing 
more spatial and temporal resolution. However, these methods each have individual 
disadvantages making the results and interpretations precarious. This has also led to 
data which are often conflicting. Despite this, several patterns have emerged giving a 
consensus to specific functions of AN. The general functions of the two structures in 
which AN occurs, the hippocampus and olfactory bulb, give clues to potential roles of 
the AN.  
The olfactory bulb is strongly associated with olfaction and although this structure has 
been much less studied than the hippocampus, data thus far indicate a role in olfactory 
learning (see Lledo et al. 2006 for review). This is supported by data indicating that 
olfactory experience can actually regulate AN in the SVZ (see Lledo et al. 2006). 
Conclusive results however remain elusive and require the application of ablation 
techniques with spatial specificity for the olfactory bulb. It has also been suggested that 
in pathological states which result in neurodegeneration the SVZ, new neurons can  
have a restorative function(Höglinger et al. 2004). However, this remains controversial, 
though the vast clinical implications of harnessing this potential for diseases such as 
Alzheimer’s, stroke and Parkinson’s disease have led to much focus on this research 
area.  
One of the main functions of the hippocampus is of learning and memory prompting 
even early studies of AN to speculate on the function of AN in learning and memory 
(Altman & Das 1967). Although not without controversy, studies have revealed 
patterns of results indicating involvement in specific functions of AN in the 
hippocampus - extensively reviewed by Deng et al. (Deng et al. 2010). Unsurprisingly 
most of these functions involve types of learning, particularly involving spatial aspects 
of learning including long-term spatial memory retention, spatial pattern discrimination 
and spatial navigation learning. Several studies also reveal an importance in modulation 
of input processing as demonstrated by involvement in contextual fear conditioning and 
trace conditioning. Emphasis has been placed on dentate gyrus dependent functions, in 
particular the critical involvement of AN in pattern separation- a process by which 
similar stimuli are discriminated (Clelland et al. 2009).  
Recently several findings have begun to describe an even more intricate relationship 
with AN and stress than previously thought and demonstrate that not only does stress 
regulate AN but that AN actually can modulate stress responses (see commentary by 
Anacker & Pariante 2011). In particular it has been suggested that a function of 
neurogenesis is to buffer stress (Snyder et al. 2011). Adaptive responses to stress are 
indeed an important function in animals with benefits for survival which have been 
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conserved (Joëls et al. 2006; Lagace et al. 2010). The importance of a proper stress 
response is highlighted in situations in which excess amounts of stress can cause a 
dysregulation of the mechanisms regulating stress responses, including AN, and lead to 
pathological conditions such as depression, a topic explored further in subsequent 
sections. 
  Although scientific innovation and dedication have revealed much about these 
described functions of AN over the past years, many questions remain unanswered and 
much is left to be discovered. However, continued effort, particularly with the 
implementation of new genetic models and techniques will undoubtedly lead to a more 
comprehensive understanding.  
 
Relevance to Disease 
An indication of the functional significance of AN are the changes seen in various 
pathologies of the central nervous system (CNS) including, among others, 
neurodegenerative disorders and neuropsychiatric diseases. Several specific 
neurodegenerative disorders have been associated with changes in AN including 
Huntington’s, Alzheimer’s and Parkinson’s diseases (PD). AN has been suggested to be 
a part of the pathology of Huntington’s disease as large decreases in hippocampal AN 
are seen in several animal models of the disease before the onset of motor symptoms 
(reviewd by Gil-Mohapel et al. 2011). Similarly, it has also been suggested that 
changes in AN might be associated with part of the pathology of  Alzheimer’s disease ( 
reviewed by Marlatt & Lucassen 2010). This hypothesis is based on  patients as well as 
a transgenic mouse model of Alzheimer’s which display changes in AN (reviewed in 
Kuhn et al. 2007). With regards to these neurodegenerative diseases, preclinical 
evidence indicates that treatments aimed at increasing deficits in AN in 
neurodegenerative disorders may have clinical impact (MacMillan et al. 2011). 
An initial study of AN in PD revealed that animal models of PD including 6-
hydroxydopamine (6-OHDA) and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
(MPTP) lesioning lead to a decrease in cell proliferation in both the SGZ as well as 
SVZ (Höglinger et al. 2004).  Further studies of AN in postmortem PD patients, using 
proliferating cell nuclear antigen (PCNA) as an endogenous marker of cell 
proliferation, revealed that this aspect of AN was decreased in the ependymal zone, the 
human equivalent to the SVZ (Höglinger et al. 2004). Subsequent publications have 
however questioned the validity of both decreases in animal models of dopamine 
lesions as well in PD patients (see table 1). Specifically, a recent publication re-
examined AN in postmortem PD patients and demonstrated, using two established 
proliferative marker and on a larger sample size than the Höglinger study, that PD 
patients did not display decreases in cell proliferation and in fact displayed no change 
(van den Berge et al. 2011). Thus the effect of this disease on AN in the lateral 
ventricles is a matter of controversy as is the effect of dopamine on AN, further 
described in subsequent sections. Depression is an aspect of PD which has often been 
overlooked but is frequently seen in patients suffering from this disorder as 
approximately one third of the patients suffering from PD exhibit clinically significant 
depressive symptoms (Reijnders et al. 2008). Neither of these human studies examined 
aspects of AN in the dentate gyrus, however, in animals models, AN in this area is 
associated with depression as described in detail below. Therefore it could be 
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speculated that changes might be present in this region in these studies particularly 
those with symptoms of depression.  
The disease group which neurogenesis has been mostly associated with are the 
neuropsychiatric disorders, particularly depression and stress related pathologies but 
also more recently schizophrenia.  
The strongest association of AN to schizophrenia are the numerous genes associated 
with the disease which have also been indicated to alter AN in animal models including 
the genes reelin, neuregulin 1, those genes related to Wnt signaling and retinoid 
signaling and one of the most associated schizophrenia genes, Disrupted in 
Schizophrenia 1 (DISC1) (see Toro & Deakin, 2007). In particular, DISC1 has been 
demonstrated to have a significant role in AN as is was shown to regulate cell 
proliferation (Y. Mao et al. 2009) as well as to regulate the integration of newborn 
neurons (Duan et al. 2007).  Furthermore, human studies have indicated that cell 
proliferation is decreased in schizophrenic patients (Reif et al. 2006). Although the 
association of AN and schizophrenia is far from established, these preliminary data 
indicate that modulation of AN may be of significance for the treatment of this 
disorder.   
Stress was one of the first exogenous factors shown to affect AN, where it was 
demonstrated that psychosocial stress decreased cell proliferation  (Gould et al. 1997). 
Subsequent studies have replicated this finding using several different paradigms and it 
is now well documented that stress, whether chronic or acute,  is one of the most potent 
suppressors of AN ( see Lucassen et al. 2010 for review). Data further show that stress 
can affect different aspects of AN by decreasing cell proliferation as described by 
Gould et al. but also by decreasing cell survival (B Czéh et al. 2001). Glucocorticoids 
are implicated in the mechanism through which this suppression occurs, although 
contradictory evidence exists indicating a deeper complexity in which other regulators 
may be involved, for example glutamate acting via NMDA receptors (Mirescu & 
Gould 2006). Evidence in support of a role of glucocorticoids come from studies 
indicating that glucocorticoids suppress cell proliferation, differentiation and cell 
survival ( Wong & Joe Herbert 2004; Wong & Herbert 2005; Wong & Herbert 2006). 
A recent study however, has investigated specific aspects of the relationship between 
stress and AN using a genetic ablation of AN (Snyder et al. 2011). Data from this study 
has revealed several important clues to this relationship. In particular, ablation of 
hippocampal AN led to a prolonged elevation of glucocorticoids in response to acute 
stress as well as a hypersecretion of glucocorticoids in response to prolonged stress 
indicating an impaired negative feedback. These results indicate that AN regulates 
endocrine stress reactivity and acts as a buffer to stress responses. The implications of 
this study are that decreases in AN as a result of an initial stress, can lead to less of a 
buffer and therefore a magnified response to repeated stress. In restricted incidents of 
stress, this mechanism may be of adaptive benefit to an animal. However, in a scenario 
of chronic or severe stress, this loop-mechanism has the potential to develop into an 
overactive, dysregulated system with the potential consequences such as symptoms 
which reflect those of depression.  
The first direct associations of AN and depression arose with the findings that a 
decreased serotonergic tone, as also seen in clinical depression, led to a decrease in AN 
(Brezun & Daszuta 1999). This and subsequent studies grounded the base for a 
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neurogenic theory of depression in which decreases in AN are proposed to be the 
causal factor in the pathophysiology of depression and furthermore that antidepressants 
ameliorate this decrease.  Indeed it was subsequently demonstrated that several 
different types of antidepressant treatments increase AN (Malberg et al. 2000;Madsen 
et al. 2000). In the absence of established depressed animal models, these experiments 
were performed in animals under normal physiological conditions and despite this, 
antidepressant treatment display a neurogenic effect. A subsequent publication 
examined the correlation of this response with behavioral effects using the novelty 
suppressed feeding (NSF) test; a behavioral paradigm in which normal animals which 
have been chronically but not acutely treated with antidepressants display a positive 
behavioral response. However, in animals with ablated neurogenesis, this  behavioral 
response was absent from fluoxetine treated animals indicating that neurogenesis was 
necessary for a response (Santarelli et al. 2003). This study appeared to cement the 
neurogenic theory of depression. Several other aspects correlated well with this theory 
including the possibility that a decrease in neurogenesis might explain the decrease in 
hippocampal brain volume seen in depressed patients and furthermore explain the time-
lag between treatment and response seen in the clinic. The neurogenic theory  as 
formalized by Jacobs et al. hypothesized that the “waning and waxing of neurogenesis 
in the hippocampal formation are important causal factors, respectively, in the 
precipitation of, and recovery from, episodes of clinical depression” (Jacobs et al. 
2000). Indeed, with the publication by Santarelli and colleagues, this theory appeared 
appealing, gaining much support but also causing much controversy. The excitement 
generated by these studies created a substantial interest in this area and resulted in 
numerous subsequent publications revolving around this topic.  
Thus, time has allowed advances as well as perspective into these matters though 
unfortunately it would appear that definitive answers remain elusive. However, studies 
regarding decreases in hippocampal volume implicate factors beyond AN indicating 
that a decrease in AN is not the reason for this change (Czéh & Lucassen 2007).   In an 
elegant review by Petrik, Lagace and Eisch, these authors categorically and 
systematically dissect the many studies produced over the past decade in an attempt to 
obtain a perspective on the current understanding of AN and depression (Petrik et al. 
2011). This review examined the postulates of the neurogenic theory investigating 
individually the consensus on the relevance of decreased AN for the pathophysiology 
of depression and accordingly the consensus on relevance of AN for the effects of 
antidepressants. These were furthermore divided into non-stressed and stressed groups. 
Thus, a consensus thus on various common depression-like behavioral tests indicates 
that neurogenic ablation does not induce depressive-like states in 76% of all tests in 
non-stressed animals and furthermore do not induced this state in 79% of tests stressed 
animals. With regards to the relevance of AN for antidepressant effects, investigations 
indicate that in 57 % of all tests in non-stressed, AN is required for antidepressant 
induced alterations in behavior whereas AN is required in 53% of tests of stressed 
animals. The NSF test alone, as described above, is one of the only tests (besides the 
modified, NSF, the NIH discussed later) which responds to chronic treatment rather 
than acute and therefore is postulated to better reflect mechanisms relevant to the clinic 
in which only chronic treatment is effective. Examination of this test alone reveals that 
12% of studies on non-stressed animals indicate that ablation of AN induces a 
depressive response in this test whereas 50% of studies in stressed animals indicate that 
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ablation of AN induces a depressive response.  Similarly examination of the relevance 
of AN for antidepressant response in this test reveals that 86% of tests in unstressed 
animals indicate a requirement of AN whereas 70% of tests in unstressed animals 
require AN for an antidepressant response. Of course, numerous factors differ between 
many of the above studies making interpretations difficult and therefore should be 
made carefully. Several factors appear to affect these studies greatly including basal 
anxiety of animals. Therefore strain, in which this varies greatly is also a factor to be 
considered. Secondly ablation method should be considered as well as antidepressant 
treatment type. Indeed several antidepressants have been shown to have antidepressant 
effects independent of AN (Sahay & Hen 2007) indicating that AN is perhaps a step 
within a mechanism.  
One pattern which appears more clear than the others is that a decrease in AN does 
not induce a depressive like phenotype in unstressed animals although NSF data cast 
doubt on this postulate in stressed animals.  There is furthermore a strong case, judging 
from these studies that in both stressed and non-stressed, AN is necessary to observe an 
antidepressants effect. Therefore a summary of the presently available data indicate that 
the original neurogenic theory of depression appears to be contradicted with regards to 
AN being an important causal factor but AN does appear important for the effect of 
antidepressant. This second postulate is indeed further supported by the fact that almost 
all currently prescribed antidepressant treatments also stimulate AN in animal models 
including SSRIs, TCAs, ECT, exercise and behavioral therapy (Malberg et al. 2000; 
Madsen et al. 2000; Bjørnebekk et al. 2005; review by Sahay & Hen 2007). However, a 
key point which is brought up in the first postulate is the question of the important 
causal factors of depression; Indeed a trend, which began with the lack of the accurate 
model of depression, was to use animals in normal physiological conditions thus 
neglecting aspects of stress.  Results from these studies have provided conflicting 
evidence as just described. However, this controversy prompted scientist to dig deeper 
into the mechanisms involved, in particular forcing the confronting of aspects of stress. 
Indeed clinical studies have long since implicated stress as a probable co-factor in the 
development of depression (see Kendler et al. 1999) as further demonstrated by 
dysregulation of the hypothalamic–pituitary– adrenocortical (HPA) axis, present in 
roughly half of depressed patients (see Swaab et al. 2005).  More recent studies have 
begun to turn this trend to once again involve aspects of stress in the study of AN and 
depression (Schloesser et al. 2009; Anacker et al. 2011; Surget et al. 2011; Snyder et al. 
2011). Ironically, controversy in procedure and subsequent results in these studies 
demonstrate that despite a decade of research into “depression” and AN, the study of 
aspects of stress are still in their infancy. Nonetheless, these studies give important 
insight into the importance of this aspect of depression and indicate that a potentially 
crucial mechanisms by which antidepressants work is via the reversal of glucocorticoid 
resistance and normalizing HPA axis hyper- activity (Anacker et al. 2011;  Surget et al. 
2011).  
Thus, a promising outcome of these recent publications will hopefully be an even more 
integrated study of the different aspects of depression including both AN and the stress 
response system. In particular, this advancement will hopefully enable experimental 
application of newly discovered modulators of neurogenesis in optimized animal 
models, in the hopes of accurately identifying clinically relevant treatments for 
disorders in which AN is affected. 
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POTENTIAL MODULATORS OF ADULT NEUROGENESIS RELEVANT TO 
STUDIES 
 
Serotonergic modulation 
One of the main reasons for the study of AN to shift  towards the study of its effect in 
depression was the original finding that decreases in serotonin using a serotonergic 
neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) in the raphe nucleus reduced cell 
proliferation and ongoing neurogenesis (Brezun & Daszuta 1999). It was quickly 
postulated that increasing serotonin would increase AN and soon thereafter it was 
reported that SSRI’s which increase serotonin levels also increased AN (Malberg et al. 
2000).  Although the effects of fluoxetine on AN may potentially involve extra-
serotonergic mechanism, studies of serotonin receptors indicate that serotonin is 
involved. Early studies suspected the 5-HT1A receptor in the proliferative effects of 
fluoxetine and results from experiments demonstrated that pharmacological antagonism 
of this receptor had detrimental effects on cell proliferation (Radley & Jacobs 2002). 
Furthermore,5-HT1A agonists increased cell proliferation in both neurogenic niches 
(Santarelli et al. 2003; Banasr et al. 2004) while this effect or the effects of fluoxetine 
were no longer present in 5-HT1A KO mice (Santarelli et al. 2003). However, no 
effects of these agonists upon cell survival have been reported indicating that the 
survival enhancing effects seen during treatment with fluoxetine (Sairanen et al. 2005) 
are mediated through a separate mechanism. Although the exact cellular distribution of 
5-HT1A is unclear, it does not appear that they are expressed in cells undergoing 
neurogenesis at any stage thus indicating an indirect mechanism by which cell 
proliferation is affected. This mechanism however remains unknown. In a further 
examination of serotonergic receptors, Banasr et al. examined several other serotonin 
receptors including the 5-HT1B receptor. Data from this experiment demonstrated that 
while in the SGZ, 5-HT1B modulation did not affect baseline levels of the different 
aspects of AN, stimulation of this receptor in serotonin depleted, neurogenesis impaired 
mice  increased cell proliferation indicating that this receptor may be of interest in 
pathological scenarios. Data from the SVZ in contrast revealed that 5-HT1B 
stimulation decreased baseline proliferation indicating differences between these 
niches. Further data from 5-HT2A and 5-HT2C revealed that only 5-HT2A affected 
AN with stimulation having a negative effect indicating and inhibitory activity in the 
SGZ which again was opposite in the SVZ.  In another study, 5-HT4 was shown to 
increase cell proliferation after remarkably sub-chronic treatment in the SGZ although 
effects were not studied in the SVZ (Guillaume Lucas et al. 2007). Further analysis of 
serotonergic effects via the 5-HT3, 5-HT6 and 5-HT7 receptors remains to be 
performed.  
 
Potential modulation of adult neurogenesis via p11 
p11, also known as S100A10, is a part of the S100 protein family – a group of proteins 
which consists of small acidic calcium binding proteins with diverse intracellular and 
extracellular functions. p11 is widely distributed in the body and brain where it is 
specifically expressed in numerous regions, including the cerebral cortex, cerebellum, 
striatum, hippocampus, hypothalamus and raphe nucleus. Several publications have 
recently demonstrated a strong correlation of p11 to depression (Svenningsson et al. 
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2006; Alexander et al. 2010; Warner-schmidt et al. 2010; Warner-schmidt et al. 2009). 
Initially in these studies, this correlation was demonstrated by the discovery that p11 
mRNA levels were decreased in a well-validated genetic mouse model of depression, 
the helpless/Rouen mice (Svenningsson et al. 2006). This finding was found to have a 
translational relevance as it was found in  addition that postmortem brains of depressed 
individuals also had decreased p11 mRNA levels (Svenningsson et al. 2006).  
Furthermore, data from p11 knock-out (KO) mice indicate that these mice have a 
depressive-like phenotype measured with two antidepressant tests and were less 
sensitive to the behavioral effects of the tricyclic antidepressant imipramine. 
Alternatively, mice that overexpressed p11 showed the opposite behavior with a less 
depressive phenotype and a normal response to antidepressants (Svenningsson et al. 
2006).  
The correlation to depression was originally demonstrated to have an association with 
the serotonergic system as it was demonstrated that p11 binds to the 5-HT1B receptor. 
As with other S100 proteins which translocate proteins, p11 was also demonstrated to 
partially regulate this receptor by increasing localization to the cell surface 
(Svenningsson et al. 2006). A subsequent publication, further supported this association 
of p11 with the serotonergic system as it was demonstrated that p11 not only binds to 5-
HT1B but also binds to the 5-HT4 receptor and similarly increases cell surface 
localization (Warner-Schmidt et al. 2009). This cell surface localization was also 
demonstrated to increase serotonergic signaling through the 5-HT4 receptor, measured 
by changes in intracellular protein concentration and phosphorylation levels (Warner-
Schmidt et al. 2009). Furthermore, p11 was shown to be required for the 5-HT4 
regulated- antidepressant behavioral effects as p11 KO mice did not respond to the 5-
HT4 partial agonist, RS67333, a drug previously shown to have antidepressant effects 
(Warner-Schmidt et al. 2009). p11 has also been shown to have effects independent of 
serotonergic modulation as it for example interacts with multiple ion channels, though 
no direct correlations to depression regarding these has been investigated 
(Svenningsson & Paul Greengard 2007). However, a serotonergic independent link for 
p11 to depression is its’ interaction with BDNF- a neurotrophic factor known to be 
highly correlated to depression. This is interaction is highlighted in a study in which 
p11 expression is shown to be regulated by BDNF (Warner-Schmidt et al. 2010). 
Subsequently 5-HT1B expression was also regulated by BDNF indicating a potential 
BDNF/p11 mediated modulation of serotonergic signaling.  Furthermore, p11 KO mice 
were shown to be  insensitive to the antidepressant actions of BDNF (Warner-Schmidt 
et al. 2010).  p11 potentially also regulates BDNF via its’ extracellular expression on 
the surface of cells where it binds tissue plasminogen activator (tPA) (Kwon et al. 
2005). tPA regulates several important structural and neurochemical aspects of 
hippocampal functions including the  activation of the protease plasmin which cleaves 
the precursor pro–BDNF to mature BDNF (Pang et al. 2004). Therefore p11 may alter 
mature BDNF levels via this mechanism though the implications of this for depression 
remains unexplored.  
These publications highlight several potential pathways through which p11 might be 
involved in the pathophysiology and possible treatment of depression. As described, 
changes in AN are another proposed component of depression and its’ treatment. The 
correlation of p11 with depression warranted therefore examination of a possible 
involvement of p11 in neurogenesis. 
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Potential modulation of adult neurogenesis via S100B 
S100B is a widely studied member of the S100 protein family, having been discovered 
before p11. In the brain, these functions include regulation of protein phosphorylation, 
calcium homeostasis, enzyme activity, protein scaffolding, and participation in 
inflammatory processes (see Donato, 2001 for review). S100B is found both 
intracellular and extracellular. As an extracellular protein it can thus act in both an 
autocrine and paracrine fashion  ( Liu & Lauder 1992).  S100B is primarily secreted by 
astrocytes, although it can also be secreted from microglia, oligodendrocytes and 
neurons (Baudry et al. 2010; Shashoua et al. 1984) and S100B can act as neurotrophin 
in small amounts but also acts as a neurotoxin inducing apoptosis in higher amounts 
(Fanò et al. 1993; Ahlemeyer et al. 2000). S100B has several specific associations to 
the serotonergic systems starting already during development where in the developing 
hippocampus serotonin mediates the release of S100B which in this case acts as a 
neurotrophin, promoting dendritic development (Mazer et al. 1997). Further support of 
a neurotrophic effect comes from a study demonstrating  that S100B overexpressing 
mice have increased axonal sprouting and neurite proliferation in the hippocampus (R. 
Reeves et al. 1994). This neurotrophic affect appears to be serotonergic system specific 
as S100B has been shown to inhibit dopaminergic neuron growth (Azmitia et al. 1990; 
Liu & Lauder 1992; Kligman & Marshak 1985). Further involvement with serotonin is 
demonstrated by the fact that stimulation of 5-HT1A receptors mediates the secretion of 
S100B in rat astrocyte cultures (Whitaker-Azmitia 1994; Ahlemeyer et al. 2000). 
Although this 5-HT1A mediated release has been disputed in vivo (Tramontina et al. 
2008), drugs which increase serotonin levels including 3,4-
Methylenedioxymethamphetamine (MDMA) and fluoxetine (SSRI) are shown to 
increase levels of S100B in the intact hippocampus (Kindlundh-Högberg et al. 2009; 
Manev 2001; Akhisaroglu et al. 2003). Furthermore, in another study, S100B levels in 
vivo were demonstrated to be positively correlated with levels of serotonin further 
indicating a serotonin dependent secretion of S100B in vivo (Haring et al. 1993). 
S100B levels have been shown to be altered in various pathologies of the nervous 
system including Alzheimer’s disease and Down syndrome (see Shapiro et al. 2010 for 
review) as well as several affective disorders including schizophrenia (Rothermundt et 
al. 2001) bipolar disorder (Machado-Vieira et al. 2002), and depression. In particular, 
increases in S100B plasma levels of depressed patients has been described in several 
studies (Grabe et al. 2001; Rothermundt et al. 2001; Arolt et al. 2003; Yang et al. 2008; 
Bernard et al. 2011). A further clinical study indicates that S100B may have a role in 
antidepressant treatment as there was a positive correlation to positive antidepressant 
response and high S100B plasma levels , measured upon admission, in depressed 
patients (Arolt et al. 2003). A recent paper has also identified fluoxetine induced raphe 
nuclei expression of S100B acting on noradrenergic neurons, which in turn induces a 
serotonergic phenotype which  ultimately contributes to antidepressant-like behavioral 
effects (Baudry et al. 2010).  
As described in the background information, AN is also associated with certain 
aspects of depression and antidepressant response. Furthermore, fluoxetine increases 
secretion of S100B in the hippocampus (Manev 2001) and fluoxetine is known to 
increase cell proliferation as well as cell survival though the mechanism through which 
this occurs is unknown although it is shown to be dependent on the 5-HT1A receptor 
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(Encinas et al. 2006; J.-W. Wang et al. 2008; Malberg et al. 2000; Santarelli et al. 
2003). 5-HT1A receptor stimulation increases the release of S100B as just described. 
Thus, these pieces of evidence convene, indicating involvement of S100B in 
neurogenesis.  This is further supported by a study in which intra-ventricular S100B 
infusion induced increases in cell proliferation and subsequent neurogenesis in the 
dentate gyrus of the hippocampus after an experimental traumatic brain injury 
(Kleindienst et al. 2005). This evidence prompted thus further studies into the 
involvement of S100B in AN. 
 
Dopaminergic modulation 
 
Potential modulation of adult neurogenesis via modulation of dopamine signaling 
 
Dopaminergic modulation of AN has recently been an area of increasing interest and 
has been the focus of numerous recent publications. From an anatomical perspective, 
dopaminergic afferents are in position to regulate neurogenesis (Freundlieb et al. 2006; 
Höglinger et al. 2004; Lennington et al. 2011). Specifically, initial anatomical study by 
Höglinger et al. used confocal microscopy combined with immunohistochemistry to 
reveal that in the SVZ midbrain dopaminergic afferents innervate the SVZ close to the 
rapidly dividing neurogenic cells (Höglinger et al. 2004). Using, a genetic model for 
dopaminergic neuron loss in the substantia nigra, the aphakia mouse, a more recent 
study specified that afferents which innervate the SVZ primarily originate from the 
ventral tegmental area, an area associated with motivation and reward 
processing(Lennington et al. 2011). Dopaminergic projections have also been shown to 
have afferents in the dentate gyrus of the hippocampus which contains the SGZ 
(Gasbarri et al. 1997; Gasbarri et al. 1994; Höglinger et al. 2004). However it is 
unknown whether these afferents originate from the ventral tegmental area or the 
substantia nigra. Of the two neurogenic niches, dopaminergic modulation of 
neurogenesis in the SVZ has been widely studied whereas few publications have 
addressed the possible dopaminergic modulation of neurogenesis in the SGZ. Therefore 
the majority of data regarding dopaminergic regulation of AN comes from studies of 
the SVZ. Studies using pharmacological tools and specific dopamine depletion 
strategies indicate that in this region, dopaminergic innervation acts to strongly regulate 
cell proliferation (see Borta & Höglinger 2007 for review). The details however of 
whether dopamine acts to increase or decrease cell proliferation in the SVZ are still far 
from clear as exhibited by conflicting results in the literature as to which receptors are 
involved and whether dopamine acts ultimately to increase or decrease cell 
proliferation.  A valuable tool to examine the effect of dopamine has been dopamine 
denervation models. While, results from several of these studies of lesion models have 
indicated that in the SVZ, dopamine depletion decreases cell proliferation (Höglinger et 
al. 2004; O’Keeffe et al. 2009; S. Baker et al. 2004), equally as many studies have 
revealed the opposite, that depletion increases cell proliferation in these models 
(Aponso et al. 2008; B. F. Liu et al. 2006; Peng et al. 2008). Furthermore, additional 
studies describe no change in cell proliferation in lesion models (Winner et al. 2009; 
van den Berge et al. 2011).  There are of course numerous factors which may have 
important implications for the outcome and interpretation of these results including 
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species, lesioning method and neurogenesis analysis method. In Table 1, a summary of 
the different lesioning studies is presented for comparison of some of these factors. 
Examination of this table reveals the numerous differences found between these studies 
and highlights the need for caution when comparing studies. This summary 
demonstrates that there is little consensus of these lesion studies as results appear to 
speak equally for both an inhibitory effect and a stimulatory effect of dopamine on cell 
proliferation (Table 1). This controversy is indicative of a complex regulation.  
An obvious possibility is that dopamine is acting on more than one of the five known 
dopamine receptors, possibly having differential effects on each receptor and/or even 
differential effects on different cell populations involved in the control of aspects of 
AN.  Knowledge regarding the actual expression of dopamine receptors is a crucial 
factor in discerning the mechanism through which dopamine affects AN, however, this 
knowledge is currently very limited due to technical limitations, in particular the lack of 
successful antibodies to identify and characterize the distribution of dopamine receptors 
in specific cell populations. Cell specific expression of dopamine receptors has been 
studied on a limited scale using alternative methods in SVZ.  In one study, Höglinger et 
al. show using SVZ derived neurosphere cultures that both D1-like receptors as well as 
D2-like receptors are expressed in cells undergoing neurogenesis in the rat (Höglinger 
et al. 2004). Kim et al. used yet another alternative technique in which they used mice 
which express GFP under either GFAP or DCX promoters. GFP positive cells from the 
adult SVZ region were then sorted using fluorescence activated cell sorting (FACS) 
into specific cell populations after which qPCR was used to determine dopamine 
receptor expression in these populations.  Results were in agreement with Höglinger et 
al and demonstrated that in the SVZ of the mouse, adult born neuroblasts express 
multiple dopamine receptors including D1, D2 and D5 but do not express the D3R 
(Kim et al. 2010). D3R expression was subsequently found in the rapidly dividing 
transit amplifying progenitor cells, indicating a direct involvement of this receptor in 
Table 1 Effects of dopaminergic denervation on adult neurogenesis in the SVZ 
Author Year Species 
Lesion 
type 
Effect 
 
Investigation 
point 
Aspect 
of AN Method 
Höglinger 2004 rat  6-OHDA ↓ n.a./n.r.  proliferation PCNA 
  
rat  6-OHDA ↓ n.a./n.r. proliferation PCNA 
  
mouse acute MPTP ↓   1,2,7 days proliferation BrdU 2 days + 0days 
  
mouse 
 
-   21,70 days proliferation BrdU 2 days + 0days 
  
mouse acute MPTP ↓ n.a./n.r. cell survival BrdU 2 days + 21days 
  
humans PD ↓ n.a./n.r. proliferation PCNA 
O'Keefe 2009 rat 6-OHDA ↓ 27 days  proliferation BrdU 6days + 1day 
  
rat 6-OHDA ↓  58 days  cell survival BrdU 6days + 21days 
Baker 2004 mouse 6-OHDA ↓ 29 days  proliferation BrdU 1day+2hrs 
  
mouse 6-OHDA ↓ 29 days  proliferation Ki-67 
Freunlieb 2006 macaques acute MPTP ↓ 5 weeks proliferation PCNA 
  
macaques acute MPTP ↓ 5 weeks ongoing neurogenesis PSA-NCAM 
Liu 2006 rat 6-OHDA ↑  14 days  proliferation BrdU  4 days + 2days 
  
rat 6-OHDA -   28 days  proliferation BrdU  4 days + 2days 
  
rat 6-OHDA ↑ n.a./n.r. ongoing neurogenesis PSA-NCAM 
van den 
 berge 2011 mouse chronic MPTP -  n.a./n.r. proliferation PCNA 
  
mouse 
 
↑ n.a./n.r. proliferation PHH3 
  
Humans PD -  n.a./n.r. proliferation PCNA 
  
Humans 
 
-  n.a./n.r. proliferation PHH3 
Peng 2008 mouse acute MPTP ↑   14 days proliferation BrdU 3 days + 4 days 
  
mouse acute MPTP ↑   14 days cell survival BrdU 3 days + 11 days 
Aponso 2008 rat  6-OHDA** -   21,70 days proliferation BrdU 1day+2hrs 
Winner  2009 rat 6-OHDA  - * n.a./n.r. 
 
BrdU (10days)+ 0 hrs 
  
rat 6-OHDA  -  * n.a./n.r. 
 
BrdU (10days) + 4 weeks 
        
** partial progressive intra-striatal 6-OHDA lesion, * indirect comparison with non- lesioned animals   
n.a./n.r. information not available or not relevant due to biomarker 
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cell proliferation in the SVZ as well as in niche astrocytes (Kim et al. 2010). Further 
information regarding the role of these specific receptors in the SVZ comes from 
studies using pharmacological tools such as agonists and antagonists for specific 
dopamine receptors. A summary of the studies examining dopaminergic modulation of 
neurogenesis using pharmacological tools is presented in table 2. Examination of these 
results indicates again numerous differing factors stressing the need for caution upon 
comparison of studies. Despite an added specificity of dopamine subtype stimulation, a 
summary of data again gives no consensus with regards to the effect of dopamine as it 
appears that both antagonists and agonists of D2 either stimulate or have no change on 
aspects of AN. Furthermore D3  
receptor stimulation appears also to either stimulate or have no changes upon AN. 
Thus, the role of dopamine in the SVZ remains a complex issue warranting further 
study. 
Dopaminergic regulation of the dentate gyrus is much less studied but the data 
available is equally filled with conflicting results. Anatomical studies in the SGZ have 
documented dopaminergic afferents to the dentate gyrus while denervation experiments 
have demonstrated both increases as well as decreases of cell proliferation indicating 
again both a stimulatory as well as an inhibitory effect of dopamine (Höglinger et al. 
2004; Peng et al. 2008; Park & Enikolopov 2010) These studies indicate again the 
Table 2 Effects of pharmacological modulation of dopamine on adult neurogenesis in the SVZ  
Author Year Species  Drug 
Primary 
 Pharmacology Dose 
Admin.  
method 
Duration 
of  
Treatment Effect 
Aspect 
of AN Method Timing 
Baker 2005 mouse  7-OH-DPAT 
D3 preferential 
 ag. 3 ug /day i.i 14 days - cp/on BrdU 14 days + 0hrs 
  mouse   U-99194A D3 antag. 4 ug /day i.i 14 days - cp/on BrdU 14 days + 0hrs 
Kim 2010 mouse  U-99194A D3 antag. 2mg/kg i.p. 3 days ↓ cs BrdU* 3 days + 5 days 
  mouse  U-99194A D3 antag. 20mg/kg i.p. 3 days ↓ cs BrdU* 3 days + 5 days 
  mouse  U-99194A D3 antag. 2mg/kg i.p. 3 days - cp BrdU 3 days + 2 hrs 
  mouse  U-99194A D3 antag. 20mg/kg i.p. 3 days ↓ cp BrdU 3 days + 2 hrs 
Van  
Kampen 2004 rat  7-OH-DPAT 
D3 preferential 
 ag. 2ug /day i.i . or i.p 14 days ↑ cp/on BrdU 14 days + 0hrs 
  rat  SKF82958 D1 ag. 2ug /day i.i .  14 days - cp/on BrdU 14 days + 0hrs 
  rat  SB 277011-A D3 antag. 1.5ug /day i.i . 4 days - cp/on BrdU 14 days + 0hrs 
Yang 2008 mouse  quinpirole D2 ag. 2 mg/kg i.p. 3 days ↑ cp BrdU 1 dose + 2 hrs 
Kippin 2005 rat  Haloperidol D2-like antag. 2mg/kg i.p. 14 days ↑ cp BrdU 1 day + 1 hr 
  rat  Haloperidol D2-like antag. 2mg/kg i.p. 
acute 6 hrs  
before 
BrdU - cp BrdU 1 day + 1 hr 
  rat  Haloperidol D2-like antag. 2mg/kg i.p. 
acute 24 
hrs 
 before 
Brdu - cp BrdU 1 day + 1 hr 
Höglinger 2004 rat   ropinirole D2 ag. 3mg/kg o.m. 
acute 45 
mins  
before 
death ↑ cp PCNA  
Wakade 2002 rat  Haloperidol D2-like antag. 0.4mg/kg d.w. 21 days - cp BrdU 1 dose + 24 hrs 
  
rat  risperidone D2-like antag.  0.5mg/kg d.w. 21 days ↑ cp BrdU 1 dose + 24 hrs 
  
rat  olanzapine D2-like antag.  2mg/kg d.w. 21 days ↑ cp BrdU 1 dose + 24 hrs 
Green et  2006 rat  olanzapine D2-like antag.  2mg/kg d.w. 21 days ↑ cp Ki-67 
 
  
rat  risperidone D2-like antag.  0.5mg/kg d.w. 21 days - cp Ki-67 
 
Wang 2004 rat  olanzapine D2-like antag.  10mg/kg d.w. 35 days ↑ cp+cs BrdU** 1 day + 14 days 
   
 olanzapine D2-like antag 10mg/kg d.w. 21 days ↑ cs BrdU** 1 day + 14 days 
   
 Haloperidol D2-like antag. 2mg/kg d.w. 35 days - cp+cs BrdU** 1 day + 14 days 
   
 Haloperidol D2-like antag. 2mg/kg d.w. 21 days - cs BrdU** 1 day + 14 days 
             
cp cell proliferation, cs, cell survival, on ongoing neurogenesis  
i.p intra-peritoneal, i.i. intra-ventricular infusion, d.w. drinking water o.m. osmotic mini-pump  
*measured in olfactory bulb, **measured in striatum 
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likely involvement of several dopamine receptors similar to the SVZ. A lack of 
successful antibodies again limits the interpretations of these studies and unfortunately 
the studies using alternative methods were limited to the SVZ and did not investigate 
the hippocampus. However, another study examined the dopamine receptor expression 
in the entire hippocampus using qPCR, which although lacking in cellular resolution, is 
able to give a quantitative measurement of receptor levels in relatively defined regions 
(Mu et al. 2011). This study demonstrated that several dopamine receptors are 
expressed in the dentate gyrus, including the D3R, albeit at low levels. Interestingly 
their data regarding other receptors is very similar to data from the SVZ found in Kim 
et al. with both studies revealing high expression of D1 and D5 receptors, suggested in 
both studies to be expressed by neuroblasts, indicating that the dopamine receptors 
expression profile of the SGZ and SVZ are indeed similar. A solution to this caveat of a 
lack of proper visualization method is the use of the recently developed technique 
which uses BAC transgenic mouse lines which allow the expression of EGFP under 
specific promoters enabling reproducible visualization of expression of a specific gene 
(Gong et al. 2003). The publicly available gene expression atlas, GENSAT 
(www.gensat.org), has mapped many proteins including the D3R using this technique. 
Data from confocal analysis which is found on this online database reveal that the D3R 
is expressed in the dentate gyrus in numerous cells along the SGZ (Figure 2). This in 
silico finding prompted us to question whether expression of D3Rs in this region has a 
role in regulation of aspects of AN. This novel information regarding D3R expressing 
cells in the SGZ combined with 
previous experiments describing 
dopaminergic modulation of cell 
proliferation indicate a possible 
relevance of this receptor for cell 
proliferation. Previous experiments 
in the SVZ indicate that D3R 
stimulation in this niche increases 
cell proliferation as exemplified by 
D3R specific agonists which 
increase cell proliferation in the rat 
SVZ (Van Kampen et al. 2004) 
whereas correspondingly, specific 
D3R antagonists decrease cell 
proliferation in the mouse SVZ 
(Kim et al. 2010). However 
modulation of this receptor in the 
SGZ has not yet been examined. 
 
 
 
 
 
Figure 2 DRD3-EGFP mice generated by GENSAT indicate 
that D3 receptors are expressed in cells along SGZ of the 
dentate gyrus in the hippocampus. (Image obtained from the 
GENSAT database  www.gensat.org) 
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AIMS 
The general aim of this thesis was to use pharmacological tools in combination with 
genetic animal models to identify potential drugs and drug targets which could be 
used to modulate aspects of adult neurogenesis in the ultimate aim of finding better 
understanding  and treatments for neuropsychiatric disorders. As a result of 
preliminary investigations and previously published data described in the 
introduction we developed the following specific aims: 
 
 
I.   Investigate the potential involvement of p11 in the process of adult 
neurogenesis by examining this process in mice which have a genetic deletion 
of the p11 gene.  
 
 
II.   Further examine p11 expression in the brain to determine areas of p 11 
expressions potentially relevant to depression or modulation of adult 
neurogenesis.   
 
 
III.   Investigate the potential involvement of S100B in the process of adult 
neurogenesis by examining this process in mice which genetically overexpress 
the S100B gene.  
 
 
IV.   Examine the potential behavioral and neurogenic effects of the mixed 
dopaminergic/serotonergic drug Sarizotan in an animal model of Parkinson’s 
disease.  
 
 
V.   Investigate the potential involvement of the D3R in the process of adult 
neurogenesis by examining this process in mice which have a genetic deletion 
of the D3R and/or mice treated with the D3 preferential antagonist, S33138.  
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METHODOLOGICAL CONSIDERATIONS 
Adult neurogenesis has only relatively recently become a general area of study in the 
field of neuroscience due in part to the rapid development of new methods making 
investigations into aspects of this complex technically reasonable. The speed of this 
development is exemplified in this thesis which has been completed over a few years 
during which this rapid development has meant that the methods used to study 
neurogenesis have evolved across the studies. The individual procedures and methods 
used for each study are described in detail the materials and methods of the associated 
paper. The main topic of AN is explored throughout the thesis and therefore the 
following is a short summary about methods chosen to study different aspects of this 
topic and a short discussion of the rationale behind these choices, as well as the 
disadvantages. 
 
Cell proliferation 
The earliest techniques with which to measure AN used [H
3
]-thymidine to label 
dividing cells which could then be visualized using autoradiographic methods (Altman 
& Das 1965).  However it was only upon the advent of BrdU to label dividing cells that 
investigations into neurogenesis began gaining momentum (Gratzner 1982; Kuhn et al. 
1996). BrdU is an exogenous thymidine analog which, similarly to [H
3
]-thymidine, 
integrates into DNA of dividing cells during S-phase when injected into animals. The 
advantage of BrdU is that it can be visualized using immunohistochemical techniques, 
allowing simple quantification of labeled cells as well as characterization of BrdU 
labeled cells with double labeling techniques. Therefore, BrdU quickly became the 
preferred techniques with which to investigate AN. A major disadvantage of BrdU 
labeling as well as other techniques currently available is that AN can only be 
examined in post-mortem tissue. Therefore, an important factor to consider when using 
BrdU is timing of the BrdU injections in relation to the time of sacrifice. Depending on 
this timing, BrdU can be used to examine different aspects of AN including cell 
proliferation, but also cell survival as discussed below. The process of proliferation is 
the point at which new cells integrate BrdU into their DNA. Already at an early point, 
1-4 days after cell division, these cells reach a critical point at which they either 
undergo apoptosis or develop into neuroblasts (Sierra et al. 2010).  Therefore, to 
accurately examine cell proliferation, animals must be sacrificed within this time point. 
In the literature, the point of sacrifice varies widely in different protocols, often from 2 
hours post injection up to several days and interpretations of these data must be made 
carefully with regards to this timing. In our initial neurogenesis experiments 
investigating cell proliferation which are included in this thesis (Paper IV), we used 
BrdU and chose to inject at four time points during an 8 hour period in order to label a 
large cohort of cells. The animals were then sacrificed 24 hours after the last injection. 
In the infancy of the study of AN, this was the preferred method of measuring cell 
proliferation; however, already at an early stage, other method of measurement  became 
evident including the use of endogenous proteins expressed during proliferation, 
particularly Ki-67 (Kee et al. 2002). Ki-67 is expressed during all stages of the mitotic 
process making it a reliable and, since its discovery, a much used marker of cell 
proliferation in the study of AN. Cell proliferation was measured using BrdU at the 
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beginning of the development of paper IV, however, the development of the paper was 
prolonged over a long period. During this time, it became increasingly popular in the 
literature to use Ki-67 for the investigation of cell proliferation and therefor it was 
decided to test this new method and complement the BrdU cell proliferation data with 
Ki-67 cell proliferation data. Results from these experiments were comparable with 
regards to tendencies although BrdU positive cell numbers were much lower (see paper 
IV) most likely due to the fact that BrdU only labels cells in S phase whereas Ki-67 is 
expressed during the entire mitotic process. The fact that Ki-67 labels such a large 
cohort is also useful for detecting subtle changes in cell proliferation and furthermore, 
successful visualization of the Ki-67 antibody does not require several pretreatment 
steps as BrdU staining. The successful application of this method in paper IV in 
addition to the benefits discussed resulted in the use of Ki-67 in all subsequent studies 
to study cell proliferation (Papers I, III and V).  
 
Ongoing Neurogenesis 
One of the first endogenous markers of AN to be widely used was doublecortin (DCX), 
a protein expressed almost exclusively in immature neurons in the neurogenic niches 
(Brown et al. 2003). Immature neurons expressing this protein are past the proliferative 
critical point and are therefore defined as true neuroblasts ceasing to express markers 
for these early cell types (Couillard-Despres et al. 2005). An initial study of the 
dynamics of this protein demonstrated that expression of DCX in cells reflect increases 
in AN induced by physical activity and seizure induction (Couillard-Despres et al. 
2005). DCX expression has since been used in numerous studies as a method with 
which to examine the levels and modulation of AN. In our studies of neurogenesis it 
was decided that, in addition to other aspects of neurogenesis, DCX measurements  
would also be used to examine possible changes in neurogenesis (Papers I,III,IV and 
V). Despite the utility of this protein, several aspects of it must be noted in order make 
interpretations from these measurements. There appears to be no consensus in the 
literature defining with regards to nomenclature what specifically DCX is measuring. 
DCX is expressed during several weeks of the process of neurogenesis where cells have 
already undergone cell proliferation but have not yet become neurons as defined by the 
expression of mature neuronal markers (Brown et al. 2003). Furthermore DCX-
expressing cells are not a homogenous group but rather a complex population of cells at 
different stages of maturation. Therefore several publications including paper I and IV 
in this thesis refer to changes in DCX simply as changes in neurogenesis. However 
upon further consideration, neurogenesis is a complex process involving many other 
steps and this nomenclature is not entirely accurate. Neither can DCX expression be 
referred to correctly as maturation as DCX expression is not only affected by 
maturation but also the size of the pool of proliferating cells present as well as the 
degree of apoptosis of these maturing cells. Therefore in order to give a more accurate 
description for this measurement we referred to it thereafter as ongoing neurogenesis in 
subsequent publications (papers III and V).  
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Cell Survival 
In terms of AN, cell survival is defined as ability of new cells to avert apoptosis and 
mature into new neurons. Under normal physiological conditions, 50% of proliferating 
cells undergo apoptosis before becoming mature neurons ( Cameron & McKay 2001). 
Cell survival is a crucial aspect for the development of new neurons which can be 
decreased under pathological conditions for example during stress (Thomas et al. 
2007). Antidepressant have on the other hand been shown to increase cell survival 
(Nakagawa et al. 2002; Sairanen et al. 2005). In particular antidepressant-mediated  
increases in cell survival is known to be independent from antidepressant effects on cell 
proliferation (Sairanen et al. 2005). Thus, this aspect of neurogenesis represents another 
point of this process which can be modulated and therefore is an important 
measurement of AN. Currently there are no known endogenous markers of new cells 
which have become mature neurons and therefore tracing methods using exogenous 
substances must be employed for the detection and characterization of cells which have 
survive. BrdU, due again to the fact that it can be visualized using 
immunohistochemical techniques has been very useful and greatly used in the literature 
for the purpose of quantifying cell survival. Differently to measuring cell proliferation, 
cell survival requires a different experiment design in which BrdU is injected, in 
rodents for example, several weeks before sacrifice. The second critical point in the 
development of new neurons, after cell proliferation, occurs before their integration into 
the neuronal circuitry and expression of the mature neuronal marker NeuN (Tashiro et 
al. 2006). Therefore cell survival experiments must be timed so that cells have had the 
chance to have passed this critical point, typically after 3 weeks. A drawback to this is 
that in each animal, BrdU can only be used to investigate one aspect, either cell 
proliferation or survival requiring separate animals for each experiment and introducing 
further variation. However, with the advent of endogenous markers such as Ki-67 to 
examine cell proliferation, these experiments can be performed in the same animals 
reducing variation, animals sacrificed as well as workload. For this however, careful 
experimental design must ensure that BrdU is only measuring survival and not cell 
proliferation; thus, drug injection must begin first after injections of BrdU. In our 
studies we thus employed this combination in order to investigate cell survival and cell 
proliferation (paper I, III and V). A drawback of BrdU is that, in contrast to most 
antigens, BrdU is tightly packed within DNA and therefore requires a harsh treatment 
using high acid concentration to denature the DNA and gain access to the epitope 
which ultimately may compromise the quality of the tissue and complicate double 
staining protocols. In initial experiments using BrdU, a neutralization step was used, as 
this was standard protocol for BrdU antibodies available (papers I, IV) adding further 
stress to the tissue. However, more newly available antibodies no longer required this 
step and therefore this step was omitted in subsequent experiments (papers III and V). 
BrdU is thus a useful method and due to lack of alternatives a currently essential 
method with which to trace and quantify new cells leading to its wide use in 
neuroscience. However it should also be noted that BrdU has several limitations 
including potential toxic or cell behavior- modulating properties (Lehner et al. 2011) 
and potentially also labels cells undergoing DNA repair and duplication (Taupin 2007). 
Therefore, interpretations of BrdU analysis must be done taking these aspects into 
consideration.  
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RESULTS AND DISCUSSION 
The following sections briefly summarize the results obtained in papers I-V. Each 
paper summary is followed by an extended discussion of the results in the perspective 
of the thesis as a whole, particularly the translational relevance of these findings. The 
reader is asked to refer to the individual articles for the actual results including 
additional data as well as detailed images and statistics.  
 
GENETIC AND PHARMACOLOGICAL MODULATION OF ADULT 
NEUROGENESIS  
 
Genetic Modulation of S100 Proteins 
Genetic ablation of p11 attenuates the neurogenic response to fluoxetine (Papers I & 
II) 
Previous publications demonstrated that the S100 protein, p11 (S100A10) has a strong 
association with depression and antidepressant treatment (see introduction for more 
detailed description) (Svenningsson et al. 2006). Furthermore, as described in the 
introduction, AN is strongly associated with depression and hence, the potential 
involvement of p11 in aspects of AN was a pressing question. We therefore designed 
experiments to examine AN by a specific genetic deletion of p11 using p11 KO mice 
which had been treated chronically with the antidepressant fluoxetine. Results from our 
experiments, presented in paper I, demonstrate that several distinct aspects of AN and 
neurogenic response to fluoxetine were altered in p11 KO mice. 
  As described in literature, mice which are treated chronically with fluoxetine exhibit 
an increase in cell proliferation, ongoing neurogenesis as well as cell survival (Encinas 
et al. 2006;Wang et al. 2008; Sairanen et al. 2005).  To examine cell proliferation we 
used the cell cycle marker Ki-67 and results from these experiments revealed an 
expected significant increase in WT mice upon chronic (21 day) treatment with 
Figure 2 Regulation of aspects of adult neurogenesis in the SGZ by fluoxetine in WT and p11 KO mice. 
(A) Histogram showing the quantification of Ki-67 positive cells representing cell proliferation. Fluoxetine 
increased cell proliferation (p<0.05) in WT but not KO mice.  (B) Histogram showing the quantification of 
DCX positive cells representing ongoing neurogenesis. Fluoxetine increased ongoing neurogenesis (p<0.05) 
in WT but not KO mice. p11 KO mice had an increased baseline level (p<0.05) of ongoing neurogenesis.  
(C) Histogram showing the quantification of BrdU positive cells representing cell survival. Fluoxetine 
increased cell survival (p<0.05) in WT but not KO mice. p11 KO mice had an increased baseline level 
(p<0.05) of cell survival. Data are reported as mean values +/- SEM. *p  .05; two-way analysis of variance 
followed by Bonferroni’s t test for pairwise comparisons. 
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fluoxetine (10mg/kg). This cell proliferative effect of fluoxetine was no longer present 
in the p11 KO mice as these mice displayed levels of cell proliferation not significantly 
different to vehicle treated mice (Fig. 2A).   Ongoing neurogenesis, measured using the 
immature neuronal marker DCX displayed results similar to cell proliferation with an 
increase in ongoing neurogenesis upon fluoxetine treatment in WT mice which was no 
longer present in p11 KO mice (Fig. 2B). Finally, survival was measured using the 
thymidine analog BrdU (3 days, 2x 75mg/kg) which was injected 3 weeks before 
sacrifice after which the number of labeled mature neurons (BrdU/NeuN positive) were 
quantified (Fig. 2C). Data from these survival experiments revealed that although 
fluoxetine increased cell survival in WT mice compared to vehicle, this cell survival 
effect does not occur in p11 KO mice as numbers of mature neurons are not 
significantly different between chronic fluoxetine and vehicle treated mice.  Thus it 
appears from these experiments that the neurogenic response to fluoxetine is attenuated 
in p11 KO mice indicating involvement of p11 in the neurogenic response to 
fluoxetine.   
Another altered aspect of AN was found in the p11 KO mice when looking at baseline 
levels of both ongoing neurogenesis and cell survival in comparison to WT mice. A 
comparison of levels of ongoing neurogenesis in vehicle treated WT and p11 KO mice 
revealed a significant increase in the p11 KO mice indicating an endogenous increased 
level of ongoing neurogenesis in these mice (Fig. 2B).. Similarly, a comparison of 
BrdU/NeuN positive cells in vehicle treated WT and p11 KO mice also revealed a 
significant increase in levels of cell survival in the p11 KO mice (Fig. 2C). No 
difference however was found in comparing baseline levels of cell proliferation 
between WT and KO mice (Fig. 2A).. 
In an attempt to elucidate the underlying mechanisms through which p11 regulates 
aspects of AN observed we performed several immunohistochemical experiments to 
determine if this mechanism was direct or indirect. Results from these experiments 
demonstrated that p11 did not appear to be expressed in either proliferating cells (Ki-67 
positive cells) or immature neurons (DCX positive cells) indicating an indirect 
regulation. It was however observed that p11 was highly expressed in cells displaying a 
large soma, characteristic of interneurons. Indeed, further staining with parvalbumin, a 
GABAergic interneuron marker revealed in fact that this marker was co-expressed by 
many of the cells highly expressing p11 indicating that a proportion of these p11 
positive cells are in fact interneurons. Further staining using markers for other types of 
interneurons, namely calbindin 28K and CCK demonstrated that highly expressing p11 
cells also co-expressed these markers. As p11 has been demonstrated to regulate 
trafficking and signaling of both the 5HT-1B and 5-HT4 receptors (Svenningsson et al. 
2006; Warner-schmidt et al. 2009), we also wanted to investigate if these receptors 
were co-expressed in these highly expressing p11 cells. Initial experiments using 
specific antibodies demonstrated that both 5HT-1B and 5-HT4 receptors were co-
expressed in these cells (paper I). Although the 5HT-1B antibody appeared to have a 
strong staining, the 5-HT4 antibody was less robust and therefore this co-expression of 
p11 and 5-HT4 in the dentate gyrus was confirmed using a 5-HT4-GFP mouse line in a 
subsequent article (paper II). In addition to being expressed in p11 positive cells, co-
expression of both 5HT-1B and 5-HT4 receptors was found in parvalbumin as well as 
calbindin interneurons in the dentate gyrus (see fig 6). Results demonstrating 
expression of both p11 and specific receptors in interneurons are interesting as they fit 
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well with previous literature which demonstrate that GABA-ergic interneurons regulate 
the differentiation, development and integration of newborn neurons (Tozuka et al. 
2005; Ge 2006) (see fig 6). As further discussed in paper I, serotonergic afferents are 
known to innervate the dentate gyrus and therefore potential modulation of signaling to 
these interneurons in p11 KO mice indicate a highly plausible mechanism through 
which p11 could affect both fluoxetine induced neurogenesis as well as basal aspects of 
maturation and survival.  However, p11 has several known interactions with other 
pathways which could ultimately affect AN including the fact that p11 interacts with 
several ion channels, and binds tissue plasminogen activator (tPA) (Svenningsson & 
Greengard 2007; Kwon et al. 2005). The interaction with tPA is particularly pertinent 
to regulation of AN as tPA/plasmin is important for the cleavage of proBDNF to 
BDNF, a well characterized regulator of AN (Pang et al. 2004; Sairanen et al. 2005) 
(see fig 6). The degree to which p11 affects each of these proposed mechanisms, further 
affecting AN, has yet to be definitively described. In our results p11 affects both 
proliferative response as well as the cell survival response to fluoxetine. As described 
in the introduction these are two separate aspects of AN which are often regulated by 
different factors. Whether these differential responses to fluoxetine in the different 
aspects of AN in p11 KO mice are the result of p11 related changes in a single common 
mechanism or multiple mechanisms has yet to be determined. Furthermore, results 
from baseline levels of aspects of AN also demonstrated differences in p11 KO mice, 
particularly in ongoing neurogenesis and cell survival. One possible explanation of the 
observed increase in DCX is a decreased maturation rate resulting in a larger cohort of 
cells expressing DCX creating an increased  maturation window,  as has been 
suggested to occur in the modulation of aspects of AN (Wang et al. 2008). This 
increase in ongoing neurogenesis as well as in the increase seen in baseline cell survival 
could also be result of an increased promotion of survival from different factors which 
may be the result from compensatory mechanisms in p11 KO mice. For example, in 
S100B KO mice, in which there is a genetic deletion of the neurotrophic factor S100B, 
there is a compensatory 53 % increase of another neurotrophic factor, namely BDNF 
(Schulte-Herbrüggen et al. 2008). It is therefore possible that the potential modulation 
of BDNF resulting from a genetic deletion of p11 may result in altered and even 
increased levels of other neurotrophic factors which may affect, or specifically increase 
survival. In summary paper I demonstrated that genetic deletion of p11 affects the 
neurogenic response to fluoxetine indicating that p11 may be involved in this response.  
 
Genetic amplification of S100B expression increases cell proliferation (Paper III) 
Previous publications have indicated the involvement of an additional S100 protein, 
S100B in both the pathophysiology of depression but also its involvement in 
antidepressant actions (Grabe et al. 2001; Manev & Manev 2001).  Furthermore, it has 
been suggested that S100B can also affect AN in the SGZ of the hippocampus under 
certain conditions (Kleindienst et al. 2005). To further examine this potential 
modulation of AN, in paper III, we examined different aspects of hippocampal AN in 
S100B TG mice which overexpress this protein. To examine cell proliferation we 
quantified Ki-67 positive cells in the SGZ. Results from this experiment demonstrated 
that S100B TG mice had significantly increased baseline levels of cell proliferation in 
comparison to WT mice (Fig. 3A). We also examined ongoing neurogenesis using 
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DCX and finally cell survival by quantifying BrdU positive cells (3 days, 2x 75mg/kg- 
3 weeks post injection). Levels of both ongoing neurogenesis and cell survival in 
S100B TG mice were similar to WT mice indicating that there was no difference in 
baseline levels of either of these parameters (Fig. 3B,C)..  As S100B and p11 both 
belong to the S100 family, it could be speculated that they have related functions. p11 
KO mice, as described in the preceding section (data from paper I), have an attenuated 
response to fluoxetine in several aspects of the neurogenic process. As described in the 
introduction, S100B is similarly to p11 related to several aspects of serotonergic 
signaling, though these are distinctly different from p11. We therefore also analyzed the 
neurogenic response of S100B TG mice after chronic treatment with fluoxetine 
(10mg/day for 21 days).  Cell proliferation in these treated WT mice displayed a 
significant increase which was seen as a 33 % induction in comparison to vehicle (Fig. 
3A,D). S100B TG mice displayed a 14 % induction in response to fluoxetine which 
was not as robust as in the WT mice and does not reach significance in post hoc 
analysis (Fig. 3A,D). This could possibly be the result of a lack of effect of fluoxetine 
in the S100B TG mice or as a result of the described baseline increase leading to a 
maximum ceiling effect being reached upon further increases with fluoxetine. 
Statistical analysis of induction levels demonstrates however no significant difference 
in response to fluoxetine between S100B and WT mice (Fig. 3D). The response to 
fluoxetine was also similar in S100B TG and WT mice when examining ongoing 
neurogenesis where there was an overall significance of treatment using two-way 
ANOVA as seen by the 27 % and 16 % induction in WT and S100B TG mice 
respectively (Fig. 3B,E). Individual post-hoc analysis did not reveal significance in 
either group, however, analysis of induction displayed no differences between S100B 
Figure 32Regulation of aspects of adult neurogenesis in the SGZ by fluoxetine in WT and S100B TG mice. 
(A-C) Histogram showing the quantification of Ki-67(A), DCX (B) and BrdU (C) positive cells representing 
cell proliferation, ongoing neurogenesis and cell survival respectively. (A) Two-way ANOVA demonstrates a 
highly significant (p<0.01) difference in treatment and a significant difference (p<0.05) in genotype but no 
significant interaction (p>0.05). Post hoc analysis revealed a significant increase (p<0.05) upon chronic 
treatment with fluoxetine in WT mice and a significant increase (p<0.05) in baseline levels of cell 
proliferation in the S100B TG mice compared with WT. (B) Two-way ANOVA demonstrates a significant 
difference (p<0.05) in treatment but not for genotype or interaction (p>0.05). Post-hoc analysis revealed no 
significant individual increases upon treatment with fluoxetine despite induction (E). Two-way ANOVA 
demonstrates a highly significant difference (p<0.01) in treatment but not for genotype and no significant 
interaction. Post-hoc analysis revealed a significant difference in cell survival upon treatment with fluoxetine 
in WT mice (p<0.05). (D-F) Data presented as a percent of induction with fluoxetine in comparison to 
vehicle reveals no significant difference between fluoxetine induction in the WT and TG mice with regards to 
cell proliferation (D), ongoing neurogenesis (E) or cell survival (F). Data are reported as mean values +/- 
SEM. *p < .05 Newman-keuls. 
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TG or WT mice indicating no difference in induction as a result of fluoxetine treatment 
(Fig. 3E). Finally analysis of the effect on cell survival in response to fluoxetine 
demonstrated a highly significant effect of treatment and no significant difference in 
induction with 38 % in WT mice and 34 % induction in S100B TG mice (Fig. 3C,F). 
Post hoc analysis revealed significant increases in WT mice which did not reach 
significance in S100B mice despite the large induction. Thus, analysis of induction in 
response to fluoxetine reveals that there are no significant differences in any of the 
aspects of AN measured indicating that the neurogenic response to fluoxetine is 
unchanged in S100B TG mice.   
The difference thus in S100B TG mice in comparison to WT is that these mice have 
an increased baseline level of cell proliferation while their neurogenic response to 
fluoxetine appears unaltered. These results indicate that a S100B can stimulate cell 
proliferation in the adult hippocampus. Indeed it is interesting to speculate whether the 
documented neurogenic effects of fluoxetine are at least in part mediated by S100B. 
This possible mechanism is supported by several lines of evidence in the literature. This 
includes the facts that S100B is primarily expressed in the hippocampus by astrocytes 
which are also known to be the source of the majority of the 5-HT1A expression in the 
hippocampus, while stimulation of this receptor induces the release of S100B in rat 
astrocyte cultures (Whitaker-Azmitia et al. 1990). Furthermore, acute stimulation with 
5-HT1A agonists and chronic treatment with fluoxetine increases cell proliferation; 
both effects of which are ablated in 5-HT1A KO mice (Santarelli et al. 2003). 
Additional support of S100B mediated effects of fluoxetine on AN comes from the 
facts that fluoxetine increases S100B in the hippocampus and furthermore that 
fluoxetine specifically targets cell  proliferation by targeting the amplifying progenitor 
cells (Encinas et al. 2006; Manev 2001).  
Several interesting questions regarding this proposed mechanism remain to be 
answered including whether or not S100B has a role in the regulation of AN during 
physiological conditions  or is only involved during increased expression for example 
during fluoxetine treatment. Our observation that an overexpression of S100B increases 
cell proliferation suggests that S100B acts to increase cell proliferation during when 
stimulated to for example during treatment. However, whether or not blockade of 
normal endogenous levels of S100B would also affect cell proliferation must be 
determined in order to answer this. Questions also remain regarding the further 
mechanism through which increased expression of S100B affects cell proliferation. 
Proliferative effects of S100B could be the result of indirect involvement but could also 
be the result of a direct effect on progenitor cells such as the amplifying progenitor cells 
described by Encinas et al. (Encinas et al. 2006) (see fig 6). Interestingly, the S100B 
receptor RAGE has been demonstrated to be expressed on newly divided cells in the 
adult SGZ indicating a direct involvement via this receptor (Manev et al. 2003) (fig 6). 
In a further publication, in vitro treatment of adult neural progenitors derived from the 
SVZ with S100B stimulated cell-proliferation adding further support to this proposed 
direct mechanism (Meneghini et al. 2010). An interesting study to further confirm this 
would be to examine the effects of fluoxetine in S100B KO mice which have been 
studied with regards to several other processes but not AN (Nishiyama et al. 2002; 
Schulte-Herbrüggen et al. 2008). It could thus be hypothesized that if S100B was 
important for baseline cell proliferation or antidepressant induced proliferation, AN 
would be correspondingly decreased in one or both of these parameters. However, it 
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has also been suggested that KO mice have increased levels of BDNF, suggested as a 
compensatory mechanism, which could perhaps complicate this experiment and 
subsequent interpretations (Schulte-Herbrüggen et al. 2008).   
 
A comparison of AN in S100B overexpressing and p11 KO mice gives a clue to the 
similarities and differences in function on AN of these S100 proteins. The neurogenic 
response to fluoxetine of S100B TG mice appeared similar to that of WT mice which is 
in contrast to what was observed in the p11 KO mice where there was a clear lack of 
induction in all aspects of AN. Examination of baseline levels further highlight 
differences where S100B TG mice display increased levels of cell proliferation, p11 
KO mice have normal levels. However, examining ongoing neurogenesis and cell 
survival reveals that baseline levels are normal in S100B TG mice while p11 KO mice 
have increased levels in both parameters. When comparing these results it must be kept 
in mind that while one mouse line lacks a protein, the other line has an excess of a 
protein. Interpretations of these result indicate that S100B to acts to stimulate cell 
proliferation in physiological conditions and/or further increase proliferation in 
response to antidepressant treatment. Results from p11 on the other hand suggest that 
p11 may inhibit cell survival in physiological conditions but acts to increase cell 
proliferation, ongoing neurogenesis and cell survival in response to antidepressant 
treatment. Thus, although there are some similarities in the functions of these proteins 
with respect to AN, their mechanisms and overall function appear quite distinct.  
 
Pharmacological Modulation of Dopaminergic and Serotonergic 
Signaling 
 
Sarizotan increases cell proliferation in neurogenic niches (Paper IV) 
Sarizotan is a drug which was developed as a potential atypical antipsychotic, similarly 
to S33138 (paper V), but was at an early stage described to be of benefit against 
extrapyramidal motor symptoms seen in Parkinson’s disease (Bartoszyk et al. 1997; 
Rabiner et al. 2002; Bibbiani et al. 2001). Sarizotan has an interesting albeit 
complicated pharmacological profile with demonstrated affinities for the 5-HT1A 
receptor but also for D2-like receptors, binding highly to D2 receptors but even higher 
to D3 and D4 receptors.  Specifically, at the 5-HT1A receptor, sarizotan has been 
proven to act as a pronounced agonist whereas its dopaminergic profile appears more 
complicated ( Bartoszyk et al. 2004). Studies have indicated that at D2 receptors, 
sarizotan may act as a partial agonist, depending on the dopaminergic impulse flow 
whereas at D3Rs, it might act as a competitive antagonist to endogenous dopamine ( 
Bartoszyk et al. 2004; Gerlach et al. 2011).  
There are several associations of these receptors with depression, AN and PD. In 
particular both 5-HT1A  as well as dopamine receptors are known to regulate aspects of 
AN and, furthermore, the 5-HT1A receptor is important for the behavioral effects of 
antidepressants (Banasr et al. 2004; Borta & Höglinger 2007; Santarelli et al. 
2003).With regards to PD, there has recently been increasing understanding that PD 
patients often also experience depression  (Chaudhuri et al. 2006; Aarsland et al. 2011).  
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Finally, decreased AN has been demonstrated to be associated with both depression and 
PD (Boldrini et al. 2009; Höglinger et al. 2004). These points thus motivated 
investigations into the possible effects of sarizotan on AN in an animal model of PD 
which are presented in paper IV.  
The animal model employed in this study was the 6-0HDA lesion model in rats. In 
addition to sarizotan, rats were also treated with the anti-parkinsonian drug L-
DOPA/benserazide either alone or in combination with sarizotan. To examine potential 
changes in AN in response to these treatments, lesioned and intact hemispheres were 
quantified for two aspects of AN including cell proliferation and ongoing neurogenesis. 
Both of these aspects were examined in the SGZ. However due to technical 
impossibilities, only cell proliferation was examined in the SVZ.  To investigate cell 
proliferation in the SGZ and SVZ, BrdU-labeled cells were quantified in these regions 
(1 day, 4x 50mg/kg- 24 hrs. post injection). Results using this method were confirmed, 
in the SGZ, by quantification of cell proliferation using endogenous Ki-67 positive 
cells. Analysis of BrdU positive cells in SVZ of the differently treated groups revealed 
that in the lesioned hemisphere, sarizotan treated rats had significantly increased levels 
of proliferation as did L-DOPA/benserazide treated rats (Fig. 4D).  Furthermore, 
combined treatment with Sarizotan and L-DOPA/benserazide induced increases 
although there was no additive effect of these drugs. In the intact hemisphere, these 
treatments induced similar though less robust increases which were insignificant upon 
Figure 4 Sarizotan induces increases in aspects of neurogenesis in an animal lesion model (A-C) Histogram 
of data from the SGZ showing the quantification of Ki-67(A), BrdU (B) and DCX (C) positive cells with Ki-
67 and BrdU both representing cell proliferation and DCX representing ongoing neurogenesis.  Results 
indicate a significant increase in cell proliferation in the lesioned side with sarizotan alone or in combination 
with L-DOPA (A,B). L-DOPA alone increased cell proliferation measured with Ki-67 but not BrdU (B). 
Sarizotan in combination with L-DOPA also increased ongoing neurogenesis in the SGZ (C). (D) Histogram 
of data from the SVZ with BrdU positive cells representing cell proliferation indicating that in the lesioned 
side sarizotan alone or in combination with L-DOPA increases cell proliferation as does L-DOPA alone. 
*p<0.05, **p<0.01 versus saline in the lesioned side.  
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statistical analysis (Fig. 4D). In vehicle treated rats, no significant difference was found 
between hemispheres in baseline levels of cell proliferation despite a slight decrease on 
the lesioned side. In the SGZ, analysis of BrdU positive cells on the lesioned side 
revealed that sarizotan significantly increased levels of cell proliferation as did 
combined treatment with L-DOPA/benserazide (Fig. 4A). L-DOPA/benserazide alone 
however did not increase cell proliferation measured using BrdU. Results from Ki67 
analysis in the SGZ confirmed these results with significant increases found with both 
sarizotan alone and in combination with L-DOPA/benserazide(Fig. 4B). Furthermore, 
Ki-67 analysis also found an increase in cell proliferation upon treatment with L-
DOPA/benserazide alone. Ongoing neurogenesis was quantified using DCX and 
analysis of DCX positive cells in the SGZ revealed similar tendencies to proliferation 
data, with a trend to increase upon treatment with sarizotan. However, only a 
combination of sarizotan and L-DOPA/benserazide induced a significant increase (Fig. 
4C). Results from the non-lesioned hemisphere displayed similar tendencies in both cell 
proliferation and ongoing neurogenesis though in comparison to vehicle, none of these 
differences were found to be significantly different. No significant differences were 
found between hemispheres in baseline levels of cell proliferation or ongoing 
neurogenesis in the SGZ. 
As described in the introduction, the effects of dopamine on AN in the SVZ, is a 
matter of controversy. Results from several studies of lesion models have indicated 
increases in cell proliferation while equally as many have indicated decreases and 
furthermore a few studies have indicated no change (see table 1). In paper IV, the lack 
of change in baseline levels of cell proliferation between hemispheres is in finding with 
the latter of these studies describing no change. Numerous differing factors in these 
studies could affect the outcome and interpretation of the results including differences 
in strain and lesion method. However in close analysis of these studies (table 1), 
differences in strain or method do not seem to be the decisive factor. However, the 
elapsed time between the time of lesioning and the time of cell proliferation 
investigation appears to be an important factor as all the studies indicating an increase, 
seem to be around the same period (~14 days post lesion), a time point that it not 
present in the other studies. This time point is identical to another study, albeit in the 
hippocampus, which describes a transient increase in proliferation 14 days post lesion 
as further described in paper IV(Park & Enikolopov 2010). This coincidence indicates a 
prevalent mechanism in both the SGZ and SVZ which warrants further investigation. 
As described regarding the transient increase in the SGZ in paper IV, this mechanism 
could be speculated to involve compensatory increases in dopamine receptor subtypes 
as a result of abrupt dopamine depletion and further dynamics which may further alter 
cell proliferation. 
Pharmacological manipulations of the dopamine system in paper IV further highlight 
the importance of dopaminergic regulation of AN. In paper IV, the increase in cell 
proliferation observed in the SVZ upon treatment with L-DOPA/benserazide is in 
agreement with previous findings in this region (Höglinger et al. 2004; O’Keeffe et al. 
2009) and indicates that dopamine acts to stimulate cell proliferation in the adult SVZ. 
As with the lesioning studies, studies of dopaminergic involvement in AN using 
pharmacological tools also often present with conflicting results as described in the 
introduction and table 2. Even though the details of how dopamine regulates cell 
proliferation are unclear, one consensus of these results is that dopamine appears to be a 
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potent modulator of cell proliferation. Sarizotan, as indicated above also has affinity to 
D3 and D2 dopamine receptors. D2 receptors, as described above, have been 
demonstrated to be central to dopamine related increases in cell proliferation in the 
SVZ, particularly through their release of the neurotrophin, CNTF, from D2 expressing 
niche astrocytes (Yang et al. 2008). Niche astrocytes are also known to express the 
D3R (Kim et al. 2010) and D3R stimulation has been demonstrated to increase cell 
proliferation in the SVZ (Kim et al. 2010; VanKampen et al. 2004), indicating that D3 
may also regulate the expression on CNTF and affect proliferation through this 
mechanism. Furthermore, stimulation of dopamine also regulates the release of EGF, 
another neurotrophin which is has been demonstrated to regulate cell proliferation 
(O’Keeffe et al. 2009). It is likely that the proliferative effects of sarizotan described in 
paper IV are at least partially mediated by its interaction with either or both of these 
receptors. Interestingly, these increases in proliferation were only observed to be 
significant in the lesioned side whereas, despite trends, there were no significant effects 
in the non-lesioned side. This difference is surprising considering there were no deficits 
in cell proliferation in either side where an actual deficit might otherwise facilitate a 
proliferative response upon pharmacological treatment. It could be speculated, that this 
difference is due to the fact that the dopamine denervation in the lesioned side leads to 
an up-regulation of dopamine receptors, inducing an increased sensitivity to dopamine 
modulating aspects of sarizotan and a subsequent increased proliferative response via 
the mechanisms described. Furthermore, the pharmacodynamics of dopaminergic 
aspects of sarizotan may be altered in the presence of endogenous dopamine, as has 
been previously suggested (Bartoszyk et al. 2004), in the non-lesioned side. This idea 
might further explain the fact that L-DOPA and sarizotan together were not observed to 
have additive effects.  The proliferative effects of sarizotan observed could also be 
partially mediated via the 5-HT1A agonistic properties of this drug. Indeed the 
importance of serotonin stimulation in the maintenance of AN in both neurogenic 
niches has been demonstrated and furthermore, that this maintenance is most likely 
mediated via the 5HT1A receptor (Brezun &  a Daszuta 1999; Banasr et al. 2004).   
Lesion experiments in the SGZ have, similarly to that of the SVZ, also presented 
controversial results regarding the effects of dopamine denervation with both increases 
and decreases and no changes being described (see introduction).  Results from the 
SGZ in paper IV thus demonstrating no differences in the lesioned and non-lesioned 
side are not outstanding and are furthermore similar to what was also observed in the 
SVZ in this paper. Data on the effects of L-DOPA demonstrated using BrdU indicate 
that there was no effect of this drug on cell proliferation, however using Ki-67, a 
significant effect was observed. This discrepancy could be the result of numerous 
factors including differences in representation of cell proliferation from each method, 
counting strategies using each antibody and human error. Although little has been 
published on the effects of L-DOPA in the SGZ, at least one previous publication 
described no effects of L-DOPA, similar to the BrdU data (Park & Enikolopov 2010). 
Furthermore, analysis using DCX to examine ongoing neurogenesis also indicated no 
effects of L-DOPA in the SGZ. The fact that chronic treatment with sarizotan had 
significant effects on cell proliferation in the lesioned side is interesting due to 
sarizotans’ high affinity and agonist properties on the 5-HT1A receptor. Previous 
literature regarding effects of other 5-HT1A agonists also have indicated a potent effect 
on cell proliferation in the SGZ and furthermore that these agonists no longer have a 
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proliferative effect in 5-HT1A KO mice (Banasr et al. 2004; Santarelli et al. 2003). 
These data indicate that cell proliferative effects of sarizotan are at least partially 
mediated via this receptor. SSRI’s are also known to increase cell proliferation, an 
effect which is dependent on 5-HT1A receptors (Santarelli et al. 2003). Therefore it 
could also be speculated that the mechanism of action through which sarizotan 
increases cell proliferation in the lesioned side is partially related to that of fluoxetine. 
Interestingly, 5-HT1A stimulation is also known to stimulate the release of S100B, as 
described in paper III (Whitaker-Azmitia et al. 1990). It would therefore also be 
interesting to know if the cell proliferative effects of sarizotan involve S100B (see fig 
6). Despite effects on cell proliferation, results from ongoing neurogenesis using DCX 
in the lesioned side indicate that these effects of sarizotan were not robust enough to 
induce a significant increase, although co-treatment with L-DOPA was significant 
indicating that the dopaminergic affinity of sarizotan is also involved. Interestingly, the 
effects of sarizotan on cell proliferation in the SGZ were only significant in the lesioned 
side, whereas in the non-lesioned side, this effect, although present, was not robust 
enough to be significant. The reason for this difference is perhaps due to the affinity of 
sarizotan for dopamine receptors which may also affect its proliferative effects in the 
SGZ, similarly to the SVZ. As described in the introduction, dopamine appears to 
regulate AN in the SGZ, though the details of which and how different receptors 
regulate the different aspects is unclear. Therefore speculation on which dopamine 
receptors sarizotan is affecting are even more unclear than the SVZ, though the 
mechanism could be similar. However, the difference in effect on lesion in comparison 
to non-lesioned side indicates that dopaminergic aspects of sarizotan do modulate its 
effect on cell proliferation. Although cell survival was not examined in this study, 
results from the ongoing neurogenesis experiments demonstrating no significant 
increase in sarizotan alone on ongoing neurogenesis indicate that sarizotan did not have 
effects on these maturing cells. This indicates that the effects of sarizotan on AN are 
primarily on cell proliferation and do not affect cell survival.  
 
Genetic and Pharmacological Modulation of D3 Receptor Signaling  
Genetic ablation and pharmacological blockade of the D3 receptor increases 
hippocampal cell proliferation (Paper V) 
To investigate possible changes in baseline levels AN in the D3R KO mice we 
compared different aspects of AN including cell proliferation, ongoing neurogenesis 
and cell survival in D3 KO and WT mice as presented in paper V. Half of these animals 
were treated with a preferential D3 antagonist, the results of which are presented and 
discussed in the section regarding pharmacological modulation of D3 signaling 
whereas presented here results solely describe results from investigation of the effects 
of the genetic modulation of D3 signaling.  To examine cell proliferation in these mice 
we used Ki-67 as a proliferative marker and demonstrated that in comparison to WT 
mice, the D3 KO mice displayed a significantly increased level of cell proliferation 
which was an average 48 % more than WT mice (Fig. 5A). To further investigate AN 
we also looked at ongoing neurogenesis using DCX to quantify the number of 
immature neurons. This experiment revealed a highly significant increase in the 
number of immature neurons in the D3 KO mice with an average 72 % more than WT 
mice (Fig. 5B). Finally we looked at the potential changes in cell survival in D3 KO 
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mice using BrdU/NeuN co-expression as a marker for cell survival (3 week post 
injection). Results from these experiments revealed only slightly higher (18 %), 
although not significantly different, levels of cell survival in D3 KO mice in 
comparison to WT (Fig. 5C).. In summary, results from these experiments demonstrate 
that D3 KO mice have a robust increase in levels of cell proliferation and ongoing 
neurogenesis but no significant differences in cell survival.  
In addition to examining the effects of genetic modulation of D3R signaling using 
D3R KO mice, D3R signaling was also examined in paper V via pharmacological 
modulation. In particular, the drug S33138, a preferential D3 vs. D2 dopamine receptor 
antagonist, was used to chronically treat WT mice. To investigate non-D3 related 
effects, D3R KO mice were also treated with the drug.  In parallel with the study above, 
effects of this drug on several aspects of AN were examined including cell 
proliferation, ongoing neurogenesis and BrdU as described.  In the cell proliferation 
experiment, WT mice had a 24 % increase in comparison to vehicle which was 
however not significant (Fig. 5A,D). Effects on D3 KO mice revealed a significant 
interaction of this genotype with S33138 as, in opposition to the increase seen in the 
WT mice, S33138 treated mice had a significant 22 % decrease in comparison to 
vehicle (Fig. 5A,D). S33138 induced a 28 % increase in ongoing neurogenesis in WT 
mice but this increase was again found to be insignificant (Fig. 5B,E). This induction 
was no longer present in D3 KO mice (-2%). Finally, S33138 did not have a profound 
of an effect on survival with a 6 % induction in WT mice which was not significant 
(Fig. 5C,F). However, S33138 had a significant effect on treated D3 KO mice which 
had a 40% decrease in levels of cell survival.  Overall, S33138 did not have any robust, 
significant effects in WT mice although despite this lack of significance, inductions 
Figure 5 (A) Bar graph of the number of Ki-67(A), DCX (B) and BrdU (C) positive cells representing cell 
proliferation, ongoing neurogenesis and cell survival respectively in WT and D3R KO mice treated 
chronically  with vehicle or S33138. (A) Results demonstrating a significant increase (p<0.05) in baseline 
levels of cell proliferation in the D3R KO mice and significant decrease (p<0.05) of proliferation upon 
treatment with S33138 in the D3R KO mice. (B) Results demonstrating a highly significant increase 
(p<0.001) in baseline levels of ongoing neurogenesis in the D3R KO mice. (C) Results demonstrating no 
significant difference in baseline levels of cell proliferation in the D3R KO mice or with treatment with 
S33138 in WT mice but significant decrease (p<0.05) of proliferation upon treatment with S33138 in the 
D3R KO mice. (D-F) Data presented as a percent of induction in comparison to vehicle reveals a highly 
significant difference between induction of cell proliferation (D), ongoing neurogenesis (E) and cell 
survival (F) in the WT and KO mice. Two-way analysis of variance followed by Bonferroni’s t-test * - 
p<0 .05. #### - p<0.0001, ## - p<0.01, # - p<0.05; Students t-test. 
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levels indicate that there was a slight effect of the drug. Interestingly these effects 
correlate well with baseline data from the KO mice discussed above. Particularly, the 
robust increase in baseline cell proliferation seen in the D3 KO mice is partially 
mirrored by use of a D3 antagonist in WT mice which also led to a mild increase - both 
represent a blockade of D3 signaling which resulted in an induction of cell 
proliferation. This trend was also repeated when examining ongoing neurogenesis in 
D3 KO mice and S33138 treated WT mice giving further support to a correlation. 
Effects of S33138 which are not specific to the D3R are prominent as exhibited by 
significant decreases seen in both cell proliferation and cell survival upon treatment 
with S33138 in D3 KO mice. Effects seen on these mice can largely be attributed to the 
D2 receptor to which S33138 most likely has a high affinity in the absence of the D3R. 
S33138 acting as an antagonist to D2 receptors thus appears to decrease cell 
proliferation and cell survival. This observation correlates well with several studies 
which indicate that in the SVZ as well as in the SGZ, D2 receptor stimulation increases 
cell proliferation (Höglinger et al. 2004; Yang et al. 2008). Overall, this experiment is 
an indication of a possible opposite nature of D3 vs. D2 receptors in the SGZ. On the 
one hand results with S33138 on WT mice, though not robust support the idea that 
D3Rs inhibit cell proliferation and subsequent aspects of AN in the SGZ. On the other 
hand results with S33138 in D3 KO mice further exemplify the complex nature of 
dopamine regulation on AN, demonstrating an opposite effect of probable D2 
receptors, whose mechanism is to stimulate cell proliferation and subsequent aspects of 
AN in the SGZ. 
The finding that genetic and pharmacological modulation of the D3R has direct 
consequences on cell proliferation correlates well with the consensus of previous 
publications that modulation of dopamine via different methods, using both in vitro and 
in vivo experiments, consistently alters specifically cell proliferation in both neurogenic 
niches rather than other aspects of AN (see Borta & Höglinger 2007 for review). It 
remains however unclear whether the observed effects on ongoing neurogenesis are 
also the direct result of a D3R modulation per se or an indirect result of an increased 
proliferative pool. Indeed, the robust increased level of proliferation observed would be 
expected to increase the number of immature neurons before they either undergo 
apoptosis or continue to develop into mature neurons. It is also possible that in addition 
to the mechanism through which proliferation is increased, D3Rs also regulate aspects 
of ongoing neurogenesis. For example it has been suggested that either decreasing the 
maturation rate or increasing survival of maturing neurons can both increase the levels 
of ongoing neurogenesis (Sairanen et al. 2005; Wang et al. 2008).  Literature regarding  
dopaminergic effects on AN beyond cell proliferation  indicate that dopamine  
primarily negatively modulates the activity of young neurons, particularly by inhibiting 
aspects of synaptic plasticity (Mu et al. 2011). This modulation could in theory alter the 
maturation and survival of immature neurons but this however remains to be 
determined. Therefore, the question as to whether or not there is a post-proliferative 
mechanism causing the observed increased level of ongoing neurogenesis in the D3R 
KO mice remains unanswered.   
Knowledge regarding the actual expression of dopamine receptors in the SGZ, 
particularly the D3R, is a crucial factor in discerning the mechanism through which 
dopamine affects AN, however, this knowledge is currently very limited due, as 
discussed, to a lack of successful antibodies. However as described in the introduction, 
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data from the SVZ indicate the presence of the D3R in this niche, suggesting that it 
might also be found in the SGZ. This is supported by qPCR data indicating low levels 
of D3 expression (Mu et al. 2011). This data demonstrating D3R expression in the 
dentate gyrus correlates nicely with confocal microscopy images from D3R GFP mice 
found on GENSAT which show expression of D3Rs in cells which appear to be in the 
SGZ. The identity of these cells remains currently unknown although their location in 
the SGZ and amount of expression suggests that they are proliferating cells due to the 
fact that if a gene was expressed in differentiated maturing neurons it would be 
expected that there would be greater expression which was deeper into the granular 
layer. Furthermore, the morphology of these cells with few processes differs to what is 
seen in immature neurons which already have rather developed processes. Data from 
D3R expression in the SVZ demonstrating expression of D3R in transit amplifying 
progenitor cells in this niche supports the idea that the D3R positive cells in the SGZ 
are the SGZ equivalent, namely the ANPs (amplifying neural progenitors) (see fig 6). 
Although, it cannot be assumed that the case is identical to the SVZ, previous data 
regarding expression of other receptors indicate that expression of D3R might be 
similar. Another possibility is that these cells are QNPs (quiescent neural progenitors) 
which are less abundant than the ANPs and have furthermore been suggested to be 
activated upon neurodegeneration, fitting the idea of an inhibitory activity of D3 (Park 
& Enikolopov 2010) (fig 6). 
 
If indeed, D3Rs are expressed in the ANP or QNP cells then our results demonstrating 
that a genetic ablation of the D3R results in an increase in cell proliferation would 
indicate that these receptors act directly to inhibit cell proliferation. Literature to date 
regarding dopaminergic control of hippocampal AN is as described limited and despite 
this, is conflicting as to whether dopaminergic control is stimulatory or inhibitory. The 
first paper to investigate dopaminergic control of AN in the SGZ used MPTP lesioning 
of dopaminergic projections and noticed a decrease in cell proliferation, indicating a 
stimulatory effect of dopamine (Höglinger et al. 2004). However, two subsequent 
papers demonstrate the opposite, that dopamine afferents have an inhibitory effect. One 
of these studies demonstrates that MPTP lesioning induces increases in both cell 
proliferation and ongoing neurogenesis (Peng et al. 2008). The other study also 
demonstrates that MPTP lesioning induces an increase in cell proliferation which was 
shown to be transient (Park & Enikolopov 2010). Several differing factors between 
these studies might explain the conflicting results including differences in the timing of 
post-lesion quantification, the concentration of MPTP used and the age of the animals. 
Furthermore, the results are not necessarily conflicting on all points as the first study, 
indicating  a stimulatory effect of  dopamine, did not investigate the time-point at which 
the last publications describe their observed inhibitory effect of dopamine (14 day post-
lesion) (see paper IV for further description).  
Recently it has also been described that these dopaminergic afferents produce other 
factors, as exemplified by the production of sonic hedgehog (SHH) by these neurons, 
which have an impact on aspects of AN (presentation SFN). Therefore it cannot be 
excluded that these conflicts in the literature are a result of factors other than dopamine 
which are ultimately affecting the neurogenic niches in lesioning experiments. The 
conflicts seen in these studies thus highlight potential shortcomings of lesioning 
experiments and demonstrate the need to also look at other methods with which to 
study dopamine modulation, using for example pharmacological tools and genetic 
models. Studies using pharmacological tools particularly agonists and antagonist, have 
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demonstrated the importance of D2 receptors found on niche astrocytes in the SVZ and 
SGZ which indirectly stimulate cell proliferation via the release of CNTF (Yang et al. 
2008). Although there is no data on pharmacological D3 modulation in the SGZ, 
several studies on the SVZ indicate that D3R stimulation in this area stimulates cell 
proliferation (Coronas et al. 2004; Kim et al. 2010). However this is contrary to what 
was found in other studies where no change was found upon stimulation of the D3R 
and in D3 KO mice which displayed no change in the cell proliferation in the SVZ( 
Baker et al. 2005). This discrepancy is perhaps partially resolved by mechanisms 
discussed below regarding distribution of D3 in different populations. In apparent 
contrast to these studies,   in the SGZ, we observe that a lack of D3Rs results in an 
increase in cell proliferation indicating that D3 inhibit stimulation. A careful 
examination of the literature though indicates a likely explanation involving D3Rs 
which as mentioned are also expressed on niche astrocytes in the SVZ, in addition to 
transit amplifying progenitors ( Kim et al. 2010) (see fig. 6). This study implies that it is 
expression on the progenitors which is involved in the D3 mediated stimulation of cell 
proliferation. However, data from Yang et al. indicate that this is highly unlikely due to 
the fact that CNTF KO mice have a reduced cell proliferation which is not further 
reduced as a result of dopaminergic lesions (Yang et al. 2008). This experiment 
demonstrates that dopamine stimulation of cell proliferation in the SVZ is dependent on 
CNTF expression found in niche astrocytes indicating that effects of D3R stimulation 
in the SVZ are via these cells and not directly via the proliferating cells themselves. 
Therefore the actual function in the SVZ of D3Rs found on transit amplifying 
progenitors remains unknown and could possibly have an inhibitory function, similar to 
what we describe in the SGZ. Despite the fact that D3Rs are known to be expressed in 
niche astrocytes in the SVZ, it is not known if they are also expressed in niche 
astrocytes in the SGZ.  D3R GFP expressing cells visualized in confocal images from 
GENSAT do not however resemble astrocytes with regards to size and morphology, 
indicating that SGZ niche astrocytes, in contrast to SVZ astrocytes, do not express 
D3Rs. Therefore it could be speculated that the overall effects of dopamine might also 
be differentially regulated in the SGZ in comparison to the SVZ. In summary the 
increased cell proliferation in the D3R KO mice, together with the knowledge of D3R 
expression in the SGZ might prove to be valuable clues to the regulation of dopamine 
in this neurogenic niche. Future experiments will however have to determine the 
precise relevance of these receptors to definitively determine their role in AN. 
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Figure 6 Summary figure of the speculative mechanisms described in papers I-V. In response to fluoxetine p11 is 
increased in interneurons where it potentially indirectly modulates the proliferation of ANPs and development of 
neuroblasts. Furthermore, p11 may interact with tPA/plasminogen, increasing cleavage of  proBDNF to BDNF 
thus increasing BDNF which  then affects aspects of AN. Fluoxetine also increases 5-HT which may activate 
5HT-1ARs on astrocytes causing them to release S100B which then activates rage found on ANPs causing them 
to proliferate. D3Rs found on QNPs and/or ANPs inhibit cell proliferation when activated. D3R KO mice have an 
ablation of these receptors and divide uninhibitedly . S33138 antagonizes this receptor causing an increase in 
proliferation of either QNPs and/or ANPs. D3 and D2Rs found potentially on niche astrocytes release CNTF upon 
stimulation which modulates aspects of AN. Sarizotan acts on 5-HT1ARs and potentially D2 and D3Rs, thus 
engaging the mechanisms described above. Graphics used from Ming and Song 2011. GPCR from Niko Stroth. 
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FUNCTIONAL AND TRANSLATIONAL RELEVANCE FOR 
NEUROPSYCHIATRIC DISORDERS 
Relevance of modulation of p11 for depression (Papers I &II)  
As described in the introduction, previous studies of p11 have demonstrated a 
correlation to depressive-like states in animal models as well as a correlation in humans  
and in addition p11 is associated with antidepressant treatment as it is increased by 
treatment with antidepressants (Svenningsson et al. 2006). In particular it has been 
demonstrated that p11 KO mice have a depressive-like phenotype using the using the 
tail suspension test (TST) and displayed an increased anxiety-like phenotype when 
examining thigmotaxis. These results were shown to have clinical relevance as it was 
shown that levels of p11 mRNA were decreased in post-mortem samples of brain tissue 
from depressed individuals. Results from studies of AN presented in Paper I mice 
indicate that p11 KO mice also have an attenuated neurogenic response to fluoxetine. 
Previous studies have indicated that AN  is necessary for certain behavioral responses 
to antidepressants, in particular the behavioral response in  novelty suppressed feeding 
(NSF) test (Santarelli et al. 2003). The NSF test, as described is interesting as it is one 
of the few behavioral tests which mimic the time lag seen in the clinic for 
antidepressant efficacy in that only chronic treatment has significant effects in this test. 
Furthermore, this test is known to be neurogenesis dependent whereas other 
experimental behavioral paradigms, for example the TST, are neurogenesis 
independent (David et al. 2009). To further test the functional consequences of the 
attenuated neurogenic response to fluoxetine, our collaborators tested p11 KO mice 
using the NSF test, the results of which are presented in paper I. Comparison with 
vehicle treated mice revealed no differences between WT and KO mice in the novelty 
suppressed feeding test suggesting a normal baseline phenotype in the KO mice using 
this paradigm. WT mice chronically treated with fluoxetine displayed an expected 
decreased latency to feed mice in comparison to untreated mice - a measure of 
antidepressant efficacy in this test. However, in the p11 KO mice the latency to feed 
was statistically similar in vehicle and fluoxetine treated mice, indicating that in p11 
KO mice, fluoxetine does not affect the behavioral response using this paradigm. This 
result suggests that chronic fluoxetine treatment does not have antidepressant effects in 
p11 KO mice. A lack of neurogenic effect of fluoxetine in p11 KO mice in addition to a 
lack of anti-depressive effect in p11 KO mice correlate strongly with the previously 
mentioned study demonstrating that AN is necessary for the antidepressant effect of 
fluoxetine (Santarelli et al., 2003) and indicate that p11 may be necessary for both the 
neurogenic and behavioral effects of fluoxetine.  These findings further support to the 
role of p11 in depression. A potential translation relevance of these findings is the 
indication that p11 may be crucial in being able to respond to both the behavioral as 
well as neurogenic effects of antidepressants. This role expands the translational 
relevance of p11 not only as a potential antidepressant target, though which to modulate 
depressive states, but also as a potential diagnostic target in predicting response to 
various antidepressants.  
As described, further analysis of p11 distribution in paper I indicate that expression of 
p11 in interneurons which also express 5-HT1B and 5-HT4 receptors near the SGZ of 
the hippocampus may represent a possible mechanism though which p11 can modulate 
the neurogenic process, ultimately having behavioral effects and potential translational 
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relevance. Depression is a complex disorder involving many areas of the brain beyond 
the dentate gyrus and beyond AN. In paper II, we further investigated the distribution 
of p11 cells which co-express 5-HT1B and 5-HT4 receptors in other areas of the 
hippocampus and the brain in an attempt to identify areas in which co-expression of 
p11 with these receptors may have relevance for depression. In addition to expression 
in these interneurons as described in paper I, p11 was also found to be co-expressed 
with 5-HT1B and 5-HT4 receptors in the majority of cells throughout the dentate gyrus, 
although both 5-HT1BR and p11 were expressed to a lesser extent than these 
interneurons. In addition, p11 was also co-expressed at moderate levels with these 
receptors throughout the CA3 and CA1 in the pyramidal cell layer in the hippocampus, 
although several cells displayed high expression (see figs. 3 and 4. Paper II). The 
function of p11 in these regions and potential relevance to disease has not yet been 
examined.   Among other areas beyond the hippocampus, p11 was also found to be co-
expressed with these receptors in several layers of the cingulate cortex (see fig. 1 Paper 
II). p11 was expressed throughout layers I-V of the cingulate cortex where it was 
mainly expressed with 5-HT1BR, particularly in layer V, where numerous double-
labeled cells were found though there was a subpopulation of cells expressing triple 
labeled with p11 and both receptors. Colleagues of ours are currently working a study 
demonstrating the relevance of expression in specific p11 positive cells in layer V 
(Schmidt et al., 2011-conference poster). In particular, data from this study 
demonstrates that specific genetic deletion of p11 in these cells ablates the behavioral 
response to SSRIs indicating a translational relevance of p11 expression in this region. 
Another region in which p11 was expressed was in the caudate putamen, where it was 
particularly highly expressed in both parvalbumin positive and choline acetyl-
tranferase, most likely representing GABAergic and cholinergic interneuron, where p11 
was co-expressed with 5-HT1B but not 5-HT 4. Expression in this region has particular 
translational relevance to PD as p11 expressed here has been demonstrated to be 
involved in the response to L-DOPA (Zhang et al. 2008). Although we did not 
investigate specific receptor distribution in the nucleus accumbens, a recent study has 
demonstrated that decreases of p11 in specifically this area induces a depressive-like 
phenotype which can be rescued by local-gene delivery in global-p11 KO mice 
(Alexander et al. 2010). This study has particularly interesting ramifications for 
treatment of depression using gene-therapy techniques and indicates a further 
translational relevance of p11. Finally, p11 expression was also found to be co-
expressed with the 5-HT1BR in the purkinje cells of the cerebellum. The function of 
p11 in this region and potential relevance to disease remains to be examined. Thus, our 
results regarding the effect of p11 modulation of neurogenic and behavioral response to 
fluoxetine as well as the expression of p11 with 5-HT1B and 5-HT4 receptors in other 
regions represent findings which have potential translational relevance for disease, 
particularly depression.  
 
Relevance of S100B for depression (Paper III) 
Our studies of AN in S100B TG mice in paper III revealed an increase in baseline cell 
proliferation which did not translate into changes in either ongoing neurogenesis or cell 
survival and furthermore, neurogenic induction in aspects of AN upon treatment with 
fluoxetine were similar to WT mice. We further tested the functional relevance of these 
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changes using the novelty induced hypophagia (NIH) test- a modified version of the 
NSF which was described in the previous section.  Similarly, to the NSF, the NIH test 
measures the effects of chronic but not acute antidepressant treatment and therefore 
reflects neurogenesis dependent behavioral effects in certain strains of mice (Gur et al. 
2007; David et al. 2009).  Testing of S100B TG mice in this paradigm revealed a 
similar behavioral response to fluoxetine in comparison to WT mice which according 
to literature (Santarelli et al. 2003) indicates that neurogenesis would be similar in both 
genotypes which indeed was the case in paper III. Furthermore, there were no 
significant baseline differences in WT and TG treated with vehicle in this paradigm in 
that vehicle treated WT and TG mice displayed similar behavioral responses. This 
result was also somewhat expected with respect to the neurogenesis data demonstrating 
only a change in cell proliferation and not total neurogenesis. On the other hand if total 
neurogenesis was increased in TG mice one might expect a behavioral response similar 
to animals treated with antidepressants. Despite these results demonstrating a lack of 
effect of S100B on this behavioral paradigm, S100B maintains translational potential. 
The increase in baseline levels of cell proliferation seen in the TG mice indicates that 
S100B may be of relevance during times of decreased cell proliferation- for example 
during stress, a known depressor of cell proliferation ( Gould et al. 1997). It could be 
speculated that in these situations, S100B may be of critical relevance through it effect 
on cell proliferation to regain baseline levels of neurogenesis. Although it remains to be 
confirmed, this mechanism may therefore have translational significance in situations 
in which changes brought about by stress may require additional therapy, for example 
during depression. Our data however report a similar level of anxiety in S100B TG and 
WT mice suggesting that S100B does not affect anxiety levels in non-stressed 
conditions. Interestingly, several studies demonstrate increases in serum levels in 
depressed patients (see introduction) which are potentially the result of compensatory 
mechanisms, such as the one described.  In particular, one study demonstrated that 
depressed patients with increased levels of S100B upon admission had a better 
response to antidepressant treatment (Arolt et al. 2003). A possible translational 
correlation of this human finding to our animal studies is the finding that the S100BTG 
mice displayed an increased response to fluoxetine in the tail suspension test. Thus it 
appears that although the translational relevance of modulation of S100B are not fully 
explored or understood, it remains an interesting avenue for future developments. 
 
Relevance of treatment with Sarizotan (Paper IV) 
As described, one of the proposed clinical applications of sarizotan has been to 
decrease the extra-pyramidal side effects of L-dopa treatment (Bibbiani et al. 2001). 
Our experiments, presented in paper IV attempted to examine further potential 
applications of this drug, specifically its application to modulate neurogenesis and 
depressive-like behavior. The combination of having anti-dyskinetic properties as well 
as antidepressive properties would have translational relevance to the sub-population of 
PD patients who experience depression. Results from these experiments as described 
demonstrated the ability of sarizotan to increase cell proliferation in both neurogenic 
niches. In addition to this, functional studies of behavioral consequences of sarizotan 
treatment were performed by a collaborator, and indicated antidepressant like 
properties using the forced swim test (FST) but no effect on anxiety like-behaviors, 
Results and Discussion 
  39 
measured through thigmotaxis and corner time. In addition our results recapitulated the 
anti-dyskinetic properties of sarizotan, as evaluated using measurements of abnormal 
involuntary movements (AIMS). These results indicate that sarizotan may be of 
significant clinical interest due both to its known antidyskinetic properties but also to 
potential antidepressant activity and therefore paper IV may have particular relevance 
for those PD patients who experience depression.  
 
Relevance of D3 receptor modulation (Paper V) 
In paper V we demonstrated endogenously increased baseline levels of cell 
proliferation and ongoing neurogenesis in D3R KO mice compared with WT mice, 
although no increase in levels of mature neurons was observed. Although we did not 
conduct any functional behavioral analysis in these mice, this lack of increase of mature 
neurons would indicate, according to literature (i.e. David et al., 2009), that there would 
be no baseline difference in neurogenesis dependent paradigms associated with 
depression such as the NSF or NIH tests described in preceding sections. In agreement 
with this, behavioral testing of D3R KO mice in previous publications have in one 
study demonstrated baseline levels of locomotion, anxiety and depressive- like 
behavior in these mice to be comparable with WT mice (Chourbaji et al. 2008). 
However, a subsequent publication revealed an increased cognitive performance in 
D3R KO mice measured using the passive avoidance task (Micale et al. 2010). 
Although increased cell proliferation and ongoing neurogenesis have no established 
effects on  behavior per se, it could be deducted from these publications that changes in 
these aspects of AN do not affect locomotion, anxiety and depressive- like behavior 
under normal physiological conditions. However, as passive avoidance is known to be 
a hippocampal dependent task, increases in cell proliferation and ongoing neurogenesis 
in this region may be involved in improving cognition through this mechanism, which 
potentially may become even more pronounced during pathological conditions, for 
example in schizophrenia. Interestingly, in paper V we also saw an inductive response 
on cell proliferation upon chronic treatment with the D3 preferential antagonist S33138. 
S33138 has been developed as a potential antipsychotic which has proven 
pharmacological activity in animal models of schizophrenia (Millan et al. 2008). 
Therefore, effects of this drug on cell proliferation and ongoing neurogenesis may have 
potential cognitive enhancing effects for this drug. The ramifications of this could have 
translational benefits for patients of schizophrenia who often experience cognitive 
impairments- an aspect of the pathology of which is largely untreated with currently 
available antipsychotics. Interestingly, the potential translational relevance of the D3R 
to depression is highlighted in a study demonstrating that D3R KO mice have an 
increased sensitivity to several types of antidepressants measured using FST. Although 
it is unclear about how changes in AN might affect the behavioral response to 
antidepressants, a potential connection is worth investigating. Furthermore, potential 
modulation of the aspects of AN via the D3R may be potentiated in pathological 
scenarios during for example extreme stress or depressive like states and indicates that 
targeting this receptors may have translational relevance for treatment of these 
disorders. Thus, the effects of D3 modulation on AN presented in paper V highlight the 
D3R as an interesting target in which to modulate AN, potentially having clinical 
relevance for neuropsychiatric disorders affected by changes in AN.  
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CONCLUDING REMARKS 
Petrik et al. recently coined the analogy of the hypothesis of depression as a scaffolding 
for trying to reconstruct the building- what the actual disorder is (Petrik et al. 2011). A 
portion of both proponents and opponents in the scientific community saw the theory of 
neurogenesis in depression as a scaffolding which excludes other hypotheses and can 
support itself- in essence that AN was the answer to depression. However, aspects of 
the original theory, particularly, the idea that decreased neurogenesis results in a 
depressive phenotype have been more or less disproven while other aspects suggesting 
that neurogenesis is required for antidepressants to alleviate depression are still 
challenged. A summary of studies done so far indicate that a disorder of AN does not 
explain depression, but they also indicate that it is not irrelevant either. Thus using the 
analogy, the theory of neurogenesis in depression as a scaffolding within itself does not 
appear to support the actual shape of the building (the disease). The present reality 
indicates rather that neurogenesis is part of a much larger scaffolding in which aspects 
thought to be important to the etiology of depression, represented by different theories 
such as those of monoamines and stress, combine to create a much more complex 
scaffolding. This broader view of neurogenesis reveals certain pitfalls which were 
perhaps made with the original ideas and suggest that scientists adopt a more 
integrative view of AN as has been done recently with regards to neurogenesis, stress 
and the endocrine system( a Surget et al. 2011; Anacker et al. 2011; Snyder et al. 2011). 
These studies present results suggesting that AN acts to regulate stress and therefore 
indicates less pathological relevance for neurogenic and behavioral outcomes in 
unstressed animals of which has been the focus of the majority of studies (see table 1 
and 2 Petrik et al. 2011).   
The numerous different ways in which neurogenesis can be modulated is accordingly 
indicative of the numerous ways in which AN can be defective and therefore 
differential methods may be of benefit for diseases with different pathophysiologies. 
Studies presented in this thesis have via the use of genetic manipulation as well as 
pharmacological compounds highlighted specific proteins and pharmacological targets 
which modulate aspects of neurogenesis. These studies have therefore brought 
potentially valuable information about ways in which AN could be beneficially 
modified under pathophysiological conditions in which these factors may be defective. 
Despite potential challenges with suitable animal models on which to test this 
information, hopefully future studies will be able to overcome these obstacles and use 
this information to ultimately develop more effective treatments for neuropsychiatric 
disorders.  
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CONCLUSIONS 
 
1. p11 is involved in the neurogenic and behavioral response to fluoxetine. In 
response to chronic treatment with fluoxetine, p11 KO mice lack a neurogenic 
response with regards to cell proliferation, ongoing neurogenesis and cell 
survival. This lack of neurogenic response was also reflected in behavior as p11 
KO mice also lacked a behavioral response to fluoxetine using the NSF test. 
These results indicate that p11 is important for the antidepressant effects of 
fluoxetine.  
 
2. p11 is co-expressed with 5-HT4 and 5-HT1B receptors in different regions 
associated with depression including several subregions of the hippocampus, 
cortex and caudate putamen. In the hippocampus, p11 was co-expressed in 
different types of interneurons which also expressed 5-HT4 and 5-HT1B 
receptors proximate to the dentate gyrus indicating a likely mechanism through 
which p11 affects aspects of neurogenesis.  
 
3. S100B has the potential to modulate cell proliferation but not ongoing 
neurogenesis or cell survival. Mice overexpressing S100B have increased 
baseline levels of cell proliferation, though normal levels of ongoing 
neurogenesis and cell survival. These mice also appear to have a normal 
neurogenic response to fluoxetine which was reflected in a normal behavioral 
response to fluoxetine using the NIH test. These results indicate that targeting 
S100B may be of benefit in pathologies in which cell proliferation is decreased. 
 
4. In an animal model of Parkinson’s disease, sarizotan has antidepressant-like 
properties. Chronic treatment with serotonergic/dopaminergic drug sarizotan 
increased cell proliferation in the experimentally dopamine-lesioned side of 
both the SVZ and SGZ. Combined treatment with L-DOPA increased ongoing 
neurogenesis in the SGZ. Furthermore, sarizotan had an antidepressant-like 
effect in the forced swim test while improving dyskinesia. These results indicate 
that sarizotan may have useful clinical applications in co-morbid Parkinsonism 
and depression.  
 
5. D3 receptors inhibit hippocampal cell proliferation. D3 receptor KO mice have 
robustly increased baseline levels of cell proliferation and ongoing 
neurogenesis. In correspondence to gene deletion, pharmacological blockade 
with the preferential D3 antagonist S33138 increased levels of cell proliferation. 
Collectively, these results indicate that cell proliferation can be modulated by 
targeting the D3 receptor and be of potential clinical relevance for 
neuropsychiatric disorders affected by changes in adult neurogenesis.  
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